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ABSTRACT 
Influence of diet and maternal dioxin on endocrine disruption: puberty, metabolic 
syndrome, and breast cancer 
(Under the direction of Drs. David W. Threadgill and Linda S. Birnbaum) 
 
 
Total lifetime estrogen (E2) exposure increases mammary cancer risk. TCDD indirectly 
affects E2 signaling and early life TCDD exposures are also implicated in breast cancer. 
E2 produced by adipose tissue is an underlying mechanism by which obesity contributes 
to early puberty, and if obesity and weight gain extend into adulthood, increased post-
menopausal breast cancer risk. These observations are further complicated by greater 
TCDD stores in the adipose of obese- compared to lean- individuals. How several 
environmental exposures, maternal exposure to TCDD, lifelong exposure to high fat diet 
(HFD), and pubertal exposure to DMBA, modify the mammary gland was examined. It 
was expected that HFD and maternal exposure to TCDD would increase mammary 
cancer risk, through both structural remodeling of the pubertal gland and through 
molecular changes. Interactions of these exposures and phenotypes were examined using 
several mouse strains and mouse models of breast cancer, but objectives were primarily 
pursued using the DMBA mouse model of breast carcinogenesis. Growth trajectories, 
adiposity, blood glucose levels, and mammary gland development effects of HFD and 
maternal TCDD were examined as potential causal players in DMBA carcinogenesis. The 
growth trajectory, adiposity, and fasting blood glucose were increased in DMBA on HFD 
relative to low-fat diet (LFD). Maternal TCDD exposure increased blood glucose levels 
and depressed mammary gland growth at PND in DBA/2J mice fed HFD. Maternal 
TCDD exposure also increased blood glucose levels in DMBA transiently. Mammary 
lesion incidence was increased by HFD and maternal TCDD exposure. TCDD exposure 
increased the number of terminal end buds in DMBA on LFD, but decreased them at 
PND 35 in DMBA on HFD. Among DMBA on HFD, maternal TCDD increased 
epithelial Cyp1b1 and decreased Comt mRNA in PND 50 mammary glands. Maternal 
iv 
TCDD exposure also increased Cyp1b1 in mammary tumors of offspring. Thus increased 
steady state levels of E2 and its metabolites were likely associated with increased 
mammary tumor incidence in DMBA. The interactions of HFD and maternal TCDD 
exposure on type II diabetes risk, pubertal mammary morphology, mammary tumor 
incidence and estrogen pathway regulation should be further explored. 
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 CHAPTER 1 
 
INTRODUCTION 
 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a potent polyhalogenated 
aromatic hydrocarbon (PHAH), with one of the lowest observed adverse effect levels 
(LOAELs) identified for developmental effects in animals. TCDD and other dioxins are 
persistent byproducts of industrial processes including incineration, pulp bleaching, and 
Agent Orange-production. These sources cause contamination of water and food 
resources. Because of the lipophilic nature of dioxins, the greatest source of human 
exposure is consumption of animal-based fatty foods, where dioxins bioconcentrate. In 
humans, dietary dioxin intake is correlated to net dioxin absorption (Harrad et al. 2003). 
Thus dioxins are commonly found in the adipose tissue and blood of all humans, 
including newborns (Brody et al. 2007).  
About 50 to 90% of dietary TCDD is absorbed (Huff et al. 1991). Consequently, 
TCDD levels in food are important to monitor. Compared to background levels, elevated 
TCDD levels have been detected in catfish and chicken eggs across the USA, and in 
butter, lamb fat and cottonseed oil from rural Kazakhstan (Hayward et al. 1999). 
Uzbekistani sheep fat, chicken fat and egg samples had TCDD-dominated dioxin levels 
that exceed European Commission standards (Muntean et al. 2003). Further, serum 
dioxin levels are directly correlated with consumption of beef and eggs containing 
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various levels of dioxins (Goldman et al. 2000). Exposure to dioxins in an omnivorous 
diet exceedes exposure from a vegan diet (Harrad et al. 2003), and dioxin levels in 
nursing babies exceed US and European safety standards (Brody et al. 2007). TCDD is a 
known human carcinogen that targets multiple sites (Birnbaum and Fenton 2003). 
Various lines of evidence implicate a modulatory role of TCDD in breast cancer. TCDD 
binds the aryl hydrocarbon receptor (AhR), and the complex translocates to the nucleus, 
where it binds dioxin responsive elements (DRE) (Nebert et al. 2004). DREs activate 
transcription of genes involved in estrogen (E2) metabolism and also xenobiotic 
transformation, e.g. Cyp1a1, Cyp1a2, Cyp1b1 (Nebert et al. 2004; Rushmore and Kong 
2002) (Fig. 1-1).  
The CYP1 family of proteins, induced by TCDD, have differing expression 
patterns in various organ systems.  CYP1B1 is expressed constitutively and is moderately 
inducible in steroidogenic and steroid-responsive tissues like breast (Badawi et al. 2000; 
Buters et al. 1999).  CYP1A2 is primarily expressed constitutively in the liver (Uchida et 
al. 2002). CYP1A1 is not expressed constitutively, but is inducible in most tissues, 
including breast (Badawi et al. 2000; Buters et al. 1999). Variability of CYP1A induction 
within these tissues comes from variable concentrations of endogenous and exogenous 
inducers, physiological factors interfering with various steps of the induction process, and 
genetic variation in CYP1A and AhR (Ma and Lu 2003).  CYP1A1 and CYP1B1 
induction in humans is highly variable, as are their link to cancer incidence; high 
inducibility of CYP1A1 and CYP1B1 is linked to increased breast cancer incidence in 
some populations, but not others (Justenhoven et al. 2007; Masson et al. 2005; Wen et al. 
2007).  This discrepancy may result from overly simplified or under-powered studies that 
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fail to detect gene by environment interactions on cancer risk.  For example, CYP1A1 
polymorphisms are associated with a modification of the association between breast 
cancer risk and polychlorinated biphenyl (PCB) exposure, though earlier studies found 
conflicting relationships between breast and serum PCB levels and breast cancer (Laden 
et al. 2002; Li et al. 2005b).  
Unlike many xenobiotics that activate the CYP1 family, TCDD is poorly 
metabolized. TCDD is very persistent, with a half-life of 11.0 to 24.4 days in mice 
(Gasiewicz et al. 1983; Leung et al. 1990), and over seven years in humans (Pitot III and 
Dragan 2001). TCDD clearance is also gender-dependent. Maternofetal transfer is a 
mode of TCDD excretion in females; transfer of TCDD is largely through the milk, 
though some is also transferred via the placenta (Koch et al. 1995; Sinjari et al. 1996). 
Through lactational exposure, TCDD concentrations adipose and liver of the pup 
increases (Ikeda et al. 2005). The tissue distribution of TCDD in neonates is also linked 
to dose-dependent CYP1A2 induction, where at 1 µg TCDD/ dam kg, CYP1A2 
influenced fetal concentrations but at lower doses, CYP1A2 induction did not impact 
distribution (Emond et al. 2004).  
The lactational TCDD exposure of offspring may effected by the ability of 
TCDD-exposed mothers to lactate. Gestational exposure to TCDD has been shown to 
alter mammary gland development in dams (Vorderstrasse et al. 2004). Organochlorines 
are associated with shortened breast feeding duration among mothers in Mexico and in 
North Carolina as well as decreased milk volume and lower fat content in nursing Dutch 
women (Boersma and Lanting 2000; Gladen and Rogan 1995; Rogan et al. 1987). 
Mammary glands of pregnant C57BL/6J mice exposed to TCDD during gestation weigh 
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less, have decreased branching, decreased formation of lobular alveolar structures and 
decreased expression of whey acidic protein, resulting in pup death within 24 hours of 
birth (Vorderstrasse et al. 2004). A study of gestational TCDD exposure in rats found 
decreased pup size, suggesting TCDD again disrupted dam lactation (Fenton et al. 2000). 
In rats, TCDD was shown to impact pup survival by interfering with milk production 
(Vorderstrasse et al. 2004).  While such disruptions would likely lower the total dose of 
TCDD to the pups, breast-feeding is known to lower breast cancer risk (Shantakumar et 
al. 2007).  Thus it is likely that lactation disruption due to TCDD exposure contributes to 
a net increase in rodent breast cancer risk. 
AhR and estrogen receptor (ER) orchestrate multiple gene transcription events to 
alter E2 homeostasis (Fig. 1-1). During times of cellular proliferation and carcinogenesis, 
E2 binding to ER activates the MAPK signal transduction pathway, causing increased 
Ccnd1 and Myc transcription and transition into S phase (Currier et al. 2005) Fig. 1-1). 
When mitogenic activity should cease, AhR and ER downregulate transcription of 
members of this E2-ER pathway to reduce E2 availability (Currier et al. 2005). Further, 
AhR and ER interact to increase Cyp1a1 and Cyp1b1 transcription to cause E2 
metabolism.  Yet some E2 metabolites cause DNA damage (Cavalieri and Rogan 2004; 
Yu et al. 2001) Fig. 1-1). These anti- and pro-carcinogenic TCDD mechanisms have been 
explored extensively and are reviewed in greater depth below. 
Anti-breast cancer activity of TCDD has been investigated mostly using in vitro 
(Wang et al. 1998; Wormke et al. 2003) and adult rodent models (Gierthy et al. 1993; 
Holcomb and Safe 1994). Because of mitogenic E2 activity, it is thought that E2 
metabolism by CYP1 is anti-estrogenic and decreases breast cancer risk (Holcomb and 
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Safe 1994). Transcriptional activation of Cyp1 also suppresses transcription of E2 and 
ER. When AhR and TCDD bind the DRE in the Cyp1 promoter, ER is prevented from 
binding an estrogen response element (ERE) that is required for E2 responsiveness (Safe 
et al. 2000). The indirect effect of CYP1B1 on estrogenicity is demonstrated by its loss in 
a Cyp1b1 deficient model (Takemoto et al. 2004). TCDD suppresses E2-induced cell 
proliferation in ERα positive human breast cancer cells and tumor growth rates in mice 
with xenographed tumors (Gierthy et al. 1993; Gierthy et al. 1987)Fig. 1-1). This 
decreased cell proliferation is caused by inhibition of cell cycle genes and proteins that 
E2 induce for movement into S phase (Safe et al. 2000) Fig. 1-1). TCDD also inhibits in 
vitro ERα-mediated upregulation of Esr2 (Kietz et al. 2004) and nuclear ER 
(Zacharewski et al. 1991).  
Some estrogen metabolites may increase breast cancer risk through oxidative 
stress leading to DNA damage (Cavalieri and Rogan 2004; Cavalieri et al. 1997) Fig. 1). 
AhR agonists, including TCDD, recruit ERα to CYP1A1 and CYP1B1 (Beischlag and 
Perdew 2005; Matthews et al. 2005).  This appears to occur through the direct interaction 
of AhR/Arnt and ERα (Beischlag and Perdew 2005), where ER binding to the ERE in the 
Cyp1 promoter regulates Cyp1 transcription (Tsuchiya et al. 2004). CYP1A1 and 
CYP1B1 metabolize E2 to 2OH-E2 and 4OH-E2, respectively (Hayes et al. 1996). 
However, the major E2 metabolic pathway is through formation of reactive 4OH-E2 by 
CYP1B1 (Lee and Zhu 2006). These E2-catechol metabolites are inactivated by catechol-
O-methyltransferase (COMT) or are involved in redox chemistry. Semi-quinones and 
quinones pump out reactive oxygen species (ROS; (Cavalieri and Rogan 2004). These 
ROS result in DNA stable- and depurination- adduct formation and DNA mutations 
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(Cavalieri and Rogan 2004; Chakravarti et al. 2001; DiGiovanni et al. 1986; Mitrunen 
and Hirvonen 2003). 
Human data suggests that TCDD can increase mammary cancer susceptibility. 
Dioxin exposure is associated with breast cancer in Russian woman (Revich et al. 2001). 
However most humans are exposed to a mixture of chemicals and the Russian study was 
no exception (Brody et al. 2007). In Seveso, Italy, where 45,000 persons have elevated 
TCDD in serum due to an industrial accident, a positive dose-response relationship 
demonstrates that increasing serum dioxin levels correlate to increased breast cancer 
incidence years later (Warner et al. 2002). This finding is remarkable given that 
demonstrating a positive association between hormone replacement therapy (HRT) and 
breast cancer required more than 150,000 woman (Kortenkamp 2006). Perhaps the 
infrequent association of xeno-estrogens with breast cancer risk human studies occurs in 
part because they typically fail to measure the estrogenic exposure during the appropriate 
temporal window. 
There is substantial evidence in animal models that adult disease risk can be 
modified by environmental factors early in development, and evidence of endocrine 
action on the fetal epigenome modifying adult endocrine cancers is growing (Dolinoy et 
al. 2007a; Junien and Nathanielsz 2007). Virtually all identified breast cancer risk factors 
increase exposure to E2 in one form or another, including early menarche, late 
pregnancy, short duration of breast feeding, HRT, post-menopausal obesity and total 
xeno-estrogen body burden (Clemons and Goss 2001; Ibarluzea Jm et al. 2004). Natural 
elevation in E2 during gestation is associated with increased breast cancer in offspring 
(Weiss et al. 1997).  Similarly, tamoxifen exposure during late gestation increases 
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susceptibility to DMBA-induced mammary tumors through E2 agonism, yet acts as a E2 
antagonist in the adult breast when used as a breast cancer chemotherapeutic (Hilakivi-
Clarke et al. 2000). This developmental-stage dependent estrogenicity increases the 
plausibility of TCDD acting both as a pro- and anti-estrogen. A pro-estrogenic role of 
early life TCDD exposures in modifying breast cancer susceptibility is supported by the 
Seveso study, where breast cancer incidence is associated with early life, but not late life 
TCDD exposures (Warner et al. 2002). Such observations point to the existence of 
critical periods in development that increase susceptibility of the mammary gland to 
cancer, potentially by sensitizing the gland to hormonally active chemicals. 
Unequivocal evidence from two environmental exposures supports the importance 
of early life exposures in carcinogenesis.  X-ray exposures to the fetus increased 
leukemia and other types of childhood cancer, and x-ray exposure to infants increased 
their adult breast cancer risk (Birnbaum and Fenton 2003).  The E2 agonist 
diethylstilbestrol (DES) caused rare vaginal adenocarcinomas in women who were 
exposed to DES as fetuses (Birnbaum and Fenton 2003). Californian women with high 
levels of serum DDT, another xeno-estrogen, prior to age 14 had a five-fold increased 
risk of breast cancer, but after that age, there was no relationship between serum DDT 
levels and breast cancer risk (Cohn et al. 2007).  Several of these examples suggest that 
while parental exposures may not be sufficient to induce cancer in offspring, a majority 
of parental exposures increase the susceptibility to carcinogen exposure in adult offspring 
(Birnbaum and Fenton 2003).  In other words, the children of exposed parents have a 
higher cancer incidence than those children from unexposed parents.  
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The role of early life TCDD exposure in adult mammary carcinogenesis has been 
investigated in several rodent studies. Gestational TCDD exposure doubled the frequency 
of DMBA-induced mammary adenocarcinomas in rats (Brown et al. 1998). Exposure to 
TCDD on PND 18 also increased the incidence of MNU-induced mammary tumors in 
rats (Desaulniers et al. 2001). However the window of susceptibility of breast cancer due 
to perinatal TCDD is narrow; rats were exposed to a mixture containing TCDD on PND 
21 had no dose dependent effects on mammary tumor morphology, latency or prevalence 
(Desaulniers et al. 2004).   
Evidence suggests that gestational TCDD exposures may increase breast cancer 
risk through remodeling of the developing mammary gland (Birnbaum and Fenton 2003). 
In the same model, phytoestrogen genistein, tamoxifen and TCDD gestational exposures 
increased mammary cancer risk in offspring, Brown et al. found an increase in 
undifferentiated terminal end buds (TEB), and decreased lobules in Sprague Dawley rats 
exposed to TCDD during gestation (Brown et al. 1998; Hilakivi-Clarke et al. 2000; 
Hilakivi-Clarke et al. 1999). In the control mice, TEB had differentiated mostly into 
lobules, a sign of sexual maturity of the gland. It has been known for 30 years that TEB 
undergo rapid proliferation, and the presence of these structures is a crucial element of 
susceptibility to carcinogenic initiation (Russo and Russo 1978). Together, these results 
indicate that by delaying proliferation and differentiation of pubertal mammary glands, 
TCDD extends the period that mammary glands are most susceptible to tumor-forming 
insults (Birnbaum and Fenton 2003; Brown et al. 1998).     
Similar effects have been seen in other rat strains; Long Evans rats from exposed 
grandmothers had disrupted mammary gland development (Fenton et al. 2000).  When 
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Long Evans rats were exposed to TCDD on GD 15, they had fewer than half the number 
of TEB, as well as decreased epithelial elongation, reduced alveolar buds, and lateral and 
primary branches that persisted to PND 68, long after these mammary glands normally 
mature (Fenton et al. 2002).  Mammary alterations were detected as early as PND 4, and 
the morphogenic changes seen in the maturing gland were found when TCDD exposure 
occurred at GD 15, but not at GD 21 or postnatally (Fenton et al. 2002). These 
observations further support a key role of gestational, rather than lactational, TCDD 
exposure on fetal reprogramming of the mammary gland that may result in mammary 
carcinogenesis in later life. 
Human data on developmental effects of parental exposure to TCDD are available 
(Fenton 2006). Delayed breast development in Flemish adolescents was associated with 
premenarcheal TCDD exposure (Den Hond et al. 2002). Menstrual cycle length was 
increased with premenarcheal TCDD exposure in Italians of the Seveso Women’s Health 
Study (SWHS), which monitors health outcomes in a cohort exposed to an industrial 
explosion resulting in the highest known population exposure to TCDD (Warner et al. 
2004). Early life TCDD exposure is also associated with similar endocrine defects in 
rodent offspring. Maternal TCDD caused a 30% permanent reduction in body weight as 
well as altered and likely delayed estrous cyclicity in rodents, even in doses lower than 
those producing maternal effects (Fenton et al. 2002; Flaws et al. 1997; Gray and Ostby 
1995; Wolf et al. 1999).  
Overweight and obesity have also emerged as public health issues in children and 
adults worldwide (Adair 2004; Popkin and Doak 1998; Popkin and Udry 1998). Rising 
obesity prevalence is a concern for many reasons. The risk of life threatening diseases, 
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such as diabetes and cancer, is also increased in obese persons. An American Cancer 
Society (ACS) study found that overweight women are 60% more likely to die from 
breast cancer than normal weight women (Calle et al. 2003). ACS suggests that rising 
breast cancer incidence rates may reflect increased prevalence of obesity (Jemal et al. 
2005; Society 2005). While diets high in fat and calories are associated with obesity, it is 
obesity and weight gain, and not any dietary factor, that consistently correlates with 
breast cancer risk (Michels et al. 2007). Here the links between obesity, environmental 
endocrine disruptors, and breast development and cancer are examined. 
The timing of exposure to obesity, like that of E2, plays a modulatory role on 
breast cancer risk. Adipose tissue produces E2 by aromatizing androgens, and excess 
adipose increases peripheral E2 levels (Simpson 2003). Though adipose tissue produces 
E2, it is thought that adipose production of E2 is not a major source of E2 until after 
menopause when obesity increases susceptibility to breast cancer (De Assis and Hilakivi-
Clarke 2006; Hankinson et al. 2004). Elevated steady state E2 levels in breast tissue may 
expose the breast to elevated E2-quinone metabolites, which can cause DNA damage. 
Further, obese woman with ER positive tumors have a poorer prognosis than ER negative 
tumor bearing obese women, although ER positive tumors are generally associated with a 
more positive prognosis (Maehle and Tretli 1996; Sorlie et al. 2001). This genetically 
susceptible group of obese women may be at a disproportional risk of breast cancer 
mortality because of the interaction of increased ER and its ligand, E2 (Lorincz and 
Sukumar 2006). 
Unlike postmenopausal obesity, pre-menopausal-, adolescent-, and childhood-
obesity is consistently associated with decreased breast cancer risk (Hankinson et al. 
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2004). Being overweight as a young woman may perturb the pituitary-hypothalamic axis, 
resulting in suppressed ovarian production of E2 and decreased ovulation frequency (De 
Assis and Hilakivi-Clarke 2006; Hankinson et al. 2004). This decrease in systemic E2 
exposure is thought to lower risk of breast cancer among obese premenopausal women 
(Potischman et al. 1996). However, ovariectomized mice have shorter latency and higher 
incidence when obese than when lean (Hakkak et al. 2007).  Further, prepubertal body 
mass index (BMI) correlates to BMI in young adults, and BMI in young adults correlates 
to BMI in adults (Weiderpass et al. 2004).  Since adult weight gain also increases post-
menopausal breast cancer risk, weight gain may play a key role in the transition from 
protection to danger of BMI on breast cancer risk (De Assis and Hilakivi-Clarke 2006). 
Thus it may be that extragonadal E2 production in obese young women that eventually 
contributes to increased breast cancer risk if weight gain continues into later life.  
Increased breast cancer susceptibility associated with parental exposure to TCDD 
may be altered by obesity due to the altered pharmacokinetics and bioavailability of 
TCDD. Though TCDD is lipophilic, its distribution among rodent and human tissues is 
Cyp1a2- and dose-dependent (Emond et al. 2006). Higher Cyp1a2 induction results in a 
greater portion of TCDD in liver relative to fat (Emond et al. 2004; Evans and Andersen 
2000). Given the unique pharmacokinetics of TCDD in obese women, it is likely that 
they will have different physiological responses to TCDD. 
In addition to the effect of obesity on TCDD distribution, obesity also slows 
TCDD elimination. The elimination of TCDD in obese women is slowed significantly 
with their increasing adiposity (Michalek and Tripathi 1999). Treatment of C57BL/6J 
mice with a high fat diet results in an elimination half-life of TCDD that is 2.4 and 1.4 
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times higher in liver and adipose, respectively, compared to those on a normal diet 
(DeVito et al. 2003). The dose of TCDD might further be reduced by early 
discontinuation of breastfeeding, which is a risk in woman with higher pre-pregnant BMI 
(Hilson et al. 2004). 
Obesity may also impact the elimination of TCDD through milk. Shifts in the 
milk fat content associated with a high fat diet may alter the concentration and total levels 
of TCDD lactationally excreted. In a high fat context, one would expect higher fat milk, 
but this appears not to be the case (Aoki et al. 1999).  Milk fat levels are not higher in 
obese women. TCDD does not get mobilized readily during milk production and is 
sequestered from mobilized adipose, potentially resulting in less TCDD delivered in 
obese women (Chao et al. 2005). This conclusion is supported by work in several 
mammal models. There is less dose-dependent TCDD induction of CYP1A2 in obesity-
associated diabetic C57BL/6J mice than those on a normal diet without diabetes or 
obesity (Godin et al. 2003). Oral acute 30-day LD50s of TCDD are negatively correlated 
to total body fat content (Geyer et al. 1993).  The authors suggest that storage of 
lipophilics, such as TCDD in adipose tissue acts as a detoxification mechanism by 
removing TCDD from tissues targeted for toxic action, e.g. liver and mammary organs.  
This implies that overweight and obese populations are less susceptible to TCDD toxicity 
than their normal weight counterparts. 
 In summary, mammary cancer is the second most common cancer among women, 
and its etiology consistently converges on E2 exposures from a variety of sources. The 
timing of exposure to endogenous- and exogenous-E2, obesity and TCDD also plays a 
key role in susceptibility to breast cancer. The interaction of environmental 
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susceptibilities is further complicated by genetics. Thus breast carcinogenesis results 
from a change in probability of mammary cancer occurrence through time, as the 
environment changes and the genetics respond to the changing environment.  
This dissertation aims to examine environmental exposures, and how they modify 
the molecular and physical structure of the mammary gland.  Specifically these exposures 
are maternal exposure to TCDD, lifelong exposure to high fat diet (HFD) and pubertal 
exposure to DMBA. The effects of these exposures were examined in the phenotypes of 
pubertal mammary gland development, mammary cancer incidence and pathology.  
Molecular changes potentially underlying these phenotypes were evaluated with 
particular emphasis on E2.  The physiological effects, e.g. growth trajectories, adiposity 
and blood glucose levels, of HFD and TCDD were examined as potential causal 
intermediates for the mammary gland phenotypes.  Finally, various interactions of these 
exposures and phenotypes were examined in several mouse strains and mouse  models of 
breast cancer. The central hypothesis is that HFD and gestational exposure to TCDD 
interact to increase mammary cancer risk, through both structural remodeling of the 
pubertal gland and through action on E2.  This hypothesis was primarily tested using the 
DMBA mouse model of breast carcinogenesis. 
DMBA is a polyaromatic hydrocarbon (PAH) that is frequently used to induce 
tumors in skin and mammary glands. PAHs are typically found in cigarettes and air 
pollution and these exposures have been linked to breast cancer (Brody et al. 2007). 
DMBA weakly binds AhR, causing hepatic and mammary transcription of Cyp1a1, 
Cyp1a2, and Cyp1b1 (Rowlands et al. 2001). Unlike TCDD, DMBA is a procarcinogen, 
14 
which through 7-methylhydroxylation, is activated by the P450s (Parkinson 2001). Both 
dietary constituents and TCDD have been shown to modify DMBA carcinogenesis.  
 In chapter 2, the ability of dietary fat and maternal TCDD to modify pubertal 
physiology and DMBA activation, via Cyp1 transcription, is explored in a mouse strain 
relatively resistant to AhR-mediated toxicity. Here we also examine changes in pubertal 
mammary gland remodeling and blood glucose levels that occur due to maternal TCDD 
exposure in mice, on either a HFD or a low fat diet (LFD).  
 In chapter 3, the interaction of dietary fat and maternal TCDD exposure on 
metabolic syndrome in several mouse models of breast cancer is examined.  Here, the 
body growth trajectory is modeled to explore the age at pubertal growth spurt, the rate of 
growth spurt across different models, and how these measures vary with HFD.  
Longitudinal change in blood glucose and percent body fat was also examined across 
diets and cancer models.  Lastly, changes in blood triglycerides are examined to complete 
the evaluation into what extent TCDD and HFD induce metabolic syndrome in these 
cancer models. 
 In chapter 4, the interaction of dietary fat and maternal TCDD on mammary 
cancer is examined. The mechanisms of this interaction are explored.  Pubertal mammary 
gland morphology is examined during cancer initiation and progression.  Gene expression 
changes during cancer progression are also explored.  
 In conclusion, the interactive relationships between HFD and maternal TCDD 
exposure across metabolic and mammary phenotypes are highlighted.  Exploration of the 
remaining questions ensues, with particular emphasis on future research in order to begin 
generalizing our observations to human hazard models for the overweight population. 
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FIGURE LEGEND 
 
Figure 1-1. Mechanisms of breast carcinogenesis: initiation and promotion (Cavalieri and 
Rogan 2004; DiGiovanni et al. 1986; Mitrunen and Hirvonen 2003). The effects of high-
fat diet and maternal TCDD seen in this dissertation are also shown. COMT denotes 
catechol-O-methyltransferase, CYP Cytochrome P450 Family, E2 17b-estradiol, ER 
Estrogen Receptor, OH-E2 hydroxyestradiol, Q semiquinone, SQ seminquinone. 
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CHAPTER 2 
 
 
DIETARY FAT ALTERS PUBERTAL BODY COMPOSITION AND P450 
INDUCTION FOLLOWING MATERNAL TCDD EXPOSURE IN DBA/2J MICE1  
 
ABSTRACT  
 
The increased prevalence of obesity associated with increased fat intake may 
make obese individuals uniquely susceptible to the effects of lipophilic aryl hydrocarbon 
receptor (AhR) ligands, like 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 7,12-
dimethylbenz[a]anthracene (DMBA).  TCDD exposure is known to increase risk of type 
II diabetes and to alter mammary differentiation and cancer. To investigate the 
consequences of dietary fat and maternal TCDD exposures on peripubertal body 
composition and hepatic P450 expression, we examined the susceptibility of progeny 
from DBA/2J (D2) dams exposed to TCDD on two diets. Pregnant D2 were dosed at 
mid-gestation with 1 µg TCDD/kg body weight or vehicle, and at parturition placed on 
high- (HFD) or low-fat diet (LFD).  On post-natal day 35, female progeny were weighed 
and body composition determined before dosing with DMBA, a rapidly metabolized AhR 
ligand, or vehicle. Fasting blood glucose was measured and liver and mammary glands 
collected for real time PCR and whole mount analyses. HFD increased body mass and 
                                                
1 Bittu S. Kuruvilla preformed hepatic RNA isolation, rtPCR, and real time PCR. 
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body fat, induced precocious mammary gland development, and increased ahr, relative to 
LFD. Maternal TCDD exposure increased fat pad length, Cyp1a1, and Cyp1b1 hepatic 
transcripts in the progeny. Maternal TCDD exposure decreased the size of terminal end 
buds, and pubertal DMBA exposure decreased their number. Diet modified the effects of 
maternal TCDD- and pubertal DMBA-exposures. Only in D2 progeny fed HFD did 
TCDD increase blood glucose and size of mammary fat pad, and decrease both branch 
elongation and the number of terminal end buds. DMBA depressed Cyp1b1 only in D2 
fed HFD. We conclude only D2 progeny fed HFD were at risk for developmental TCDD 
and DMBA exposure effects on pubertal blood glucose levels, mammary differentiation, 
and hepatic Cyp1b1at these doses and developmental stages. These diet by aryl 
hydrocarbon ligand exposure interactions impact major endocrine systems involved in 
pubertal maturation. 
 
INTRODUCTION  
 
Increased prevalence of childhood and adult obesity contributes to elevated risk 
for metabolic syndrome, precocious mammary development, and breast cancer 
(Carmichael 2006; Himes et al. 2004 Carmichael, 2006 #426; Hotamisligil 2006; Ogden 
et al. 2006). Total lifetime estrogen (E2) exposure increases mammary cancer risk (De 
Assis and Hilakivi-Clarke 2006). E2 produced by adipose tissue is an underlying 
mechanism by which obesity may contribute to early puberty, and if obesity and weight 
gain extends into adulthood, increased post-menopausal breast cancer risk (Britton et al. 
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2004; De Assis and Hilakivi-Clarke 2006; Hakkak et al. 2007; Simpson 2003; Stoll 
1998). 
 In addition to contributing to obesity, consumption of animal-based foods, 
frequently associated with high fat diets, is correlated with human serum and milk levels 
of dioxins (Goldman et al. 2000; LaKind et al. 2004). Increased food intake, particularly 
from a high fat diet (HFD), may alter breast cancer risk through higher intake of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD).  There is some evidence of TCDD decreasing 
breast cancer risk in vitro (Wang et al. 1998; Wormke et al. 2003), and in vivo (Holcomb 
and Safe 1994). However, human data indicates that TCDD increases mammary cancer 
risk. Women in Seveso, Italy who have elevated TCDD in their serum due to an 
industrial accident have a dose-dependent increase in breast cancer incidence (Warner et 
al. 2002). Breast cancer incidence is also increased among Russians with elevated dioxin 
exposure (Revich et al. 2001).  
  Although infants are exposed to dioxins at low doses in breast milk worldwide, 
few studies have examined developmental toxicity, or evaluated incidences of adult 
cancer (Ayotte et al. 1996; Gladen et al. 2000; LaKind et al. 2004). However, several 
animal studies have explored this relationship. Sprague Dawley rats gestationally 
exposed to TCDD developed a higher frequency of 7,12-dimethylbenz[a]anthracene 
(DMBA)-induced mammary adenocarcinomas (Brown et al. 1998). Exposure to TCDD 
on post-natal day (PND) 18 also increases the incidence of N-nitroso-N-methylurea-
induced mammary tumors in Sprague Dawley rats (Desaulniers et al. 2001). 
Polyhalogenated aromatic hydrocarbons (PHAH) and polycyclic aromatic 
hydrocarbons (PAH), like TCDD and DMBA, respectively, bind the aryl-hydrocarbon 
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receptor (AhR) to induce cytochrome P450, polypeptide 1 (CYP1) enzymes (Nebert et al. 
2004). Both CYP1B1 and CYP1A1 enzymes work in parallel to biotransform estradiol 
and DMBA into mutagenic metabolites (Cavalieri and Rogan 2004; DiGiovanni et al. 
1986). These alterations in estrogen and DMBA metabolism have been proposed as a 
mechanism for carcinogen-induced mammary cancer initiation (Cavalieri and Rogan 
2004; Zhu et al. 2008). Additionally, AhR has both pro- and anti-estrogenic cross talk 
with the estrogen receptor (ER) (Ohtake et al. 2003; Safe et al. 2000).  
These AhR-ER actions are further complicated by greater TCDD stores in the 
adipose of obese- compared to lean- individuals. The elimination of TCDD in obese 
women is slowed significantly with their increasing adiposity (Michalek and Tripathi 
1999) because of a larger volume of TCDD distribution (Emond et al. 2006). Treatment 
of C57BL/6J mice with a high fat diet resulted in elimination half-life of TCDD 2.4 and 
1.4 times longer in liver and adipose respectively, compared to those on a normal diet 
(DeVito et al. 2003).  
 Endocrine disruption by dietary fat and AhR ligands, TCDD and DMBA, may 
also increase breast cancer risk through changes in mammary gland morphology. Dietary 
fat induces precocious breast development (Britton et al. 2004). This may occur through 
adipose-driven activity of ERα and EGFR, receptors involved with pubertal mammary 
morphogenesis (Ciarloni et al. 2007; Howlin et al. 2006). In 55-day-old female rats, 
DMBA increased the number of terminal end buds and their mitotic activity (Russo and 
Russo 1978). It was thought that increased proliferation in the terminal end buds 
decreased the effectiveness of DNA repair and checkpoint responses to result in the 
formation of adenocarcinomas (Russo and Russo 1978). Conversely, gestational exposure 
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to TCDD disrupts the differentiation of mammary glands in female rat progeny (Fenton 
et al. 2002; Vorderstrasse et al. 2004). Further, as serum dioxin concentrations increased 
in girls, their pubertal breast development was delayed (Den Hond et al. 2002).  This may 
lengthen the temporal window in which glands are susceptible to insults, and ultimately 
lead to an increased instance of mammary tumor growth when adults (Birnbaum and 
Fenton 2003; Brown et al. 1998; Desaulniers et al. 2001). 
In this study, we sought to examine how maternal TCDD exposure interacts with 
dietary fat to influence postnatal physiology of DBA/2J (D2), who have a low affinity for 
AhR which makes them less sensitive to TCDD and non-responsive to PAH induction 
(Chapman and Schiller 1985; Moriguchi et al. 2003). We determined the contributions of 
both maternal TCDD exposure and dietary fat on phenotypes such as alterations in body 
mass, percentage of body fat and fasting glucose levels. Maternal TCDD slows mammary 
epithelial growth in rat offspring, and HFD and pubertal DMBA are known to accelerate 
this process. We addressed to what extent dietary fat and developmental exposures 
impact mammary glands during puberty. These studies also explored whether maternal 
TCDD exposure, dietary fat and DMBA influence mRNA expression involved with 
mammary gland differentiation and AhR ligand- and estrogen- metabolism.  
 
MATERIALS AND METHODS 
 
Chemicals. TCDD (99.9% pure, Ultra Scientific, North Kingstown, RI) and 
DMBA (98% pure, Sigma-Aldrich, St. Louis, MO) were obtained commercially.  Both 
chemicals were dissolved in 95%/5% olive oil/toluene by volume (Sigma-Aldrich). 
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DMBA and TCDD were dosed from 25 mg/ml and 500 ng/ml stock concentrations, 
respectively. These corresponded to 2.4 µl DMBA solution/g mouse and 1.8-1.9 µl 
TCDD solution/g mouse. 
 
Mice and dosing. D2 nulliparous mice (Jackson Laboratory, Bar Harbor, ME) 
were time bred and dosed with 1 µg/kg of TCDD or vehicle control by gavage at 12.5 
days post coitus, which corresponds to the time when fetal mammary fat pads are 
developing (n = 24 dams). On post-natal day (PND) 0, dams were changed from 5058 
chow (Purina) to a high-fat diet (HFD; 45% of total kcal from fat and 35% of total kcal 
from carbohydrate; D12451, Research Diets, NJ; n = 12 dams) or a low-fat matched 
control diet (LFD; 10% of total kcal from fat and 70% kcal from carbohydrate; D12450B, 
Research Diets; n = 12 dams).  Diets had the same percentage of protein, and diet 
differences were achieved by increased maltodextrin and lard, and decreased cornstarch 
and sucrose in HFD compared to LFD (400, 1598, 291, 691 kcal vs. 140, 180, 1260, 1400 
kcal respectively).  The LFD has fat levels that fall into the range often found in standard 
rodent chows. Mice had ad libitum access to feed and water.  Female pups were weaned 
at PND 21, ending any lactational exposure to TCDD, but continuing their LFD and HFD 
exposures.  Offspring were dosed with 60 mg/kg of DMBA (n = 12 litters) or vehicle (n= 
12 litters) by gavage on PND 35, when developing pubertal mammary glands are known 
to be sensitive to carcinogen exposure.  The experimental design in shown in Figure 2-1. 
Mice were euthanized 24 hours later by carbon dioxide asphyxiation. All animal 
experiments were approved by the UNC Institutional Animal Care and Use Committee 
and were performed in an AAALAC-accredited vivarium. 
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Metabolic endpoints. On PND 0, body weights were assessed by weighing the 
entire litter, and determining the average pup weight.  Individual body weights were 
measured at PND 4, 7, 10, 14, 18, 21, and 35.  On PND 35, percent body fat was 
measured with a Lunar PIXImus dual-energy X-ray absorptiometry (DEXA) scanner 
using isofluorane anesthesia (GE Lunar PIXImus Corporation, Madison, WI).  Blood 
glucose levels were measured from tail blood on PND 36 using a FreeStyle blood glucose 
kit after a 24 hour fast (Abbott Laboratories, Abbott Park, Il).   
 
Histology. Inguinal mammary glands from PND 36 were fixed and stained with 
Carmine Alum to detect terminal end buds and branch elongation according to published 
methods (Fenton et al. 2002).   
 
Molecular analyses.  At PND 36, median liver lobes and inguinal mammary 
glands were dissected, homogenized and RNA extracted.  The High Capacity cDNA 
archive kit (ABI) was used to generate cDNA for PCR analysis (Applied Biosystems, 
Foster City, CA).  Real time PCR was performed to assess relative transcript levels of 
Cyp1a1, Cyp1a2, Cyp1b1, Areg, Ereg, Ahr, Egfr and Esr1 using Assays-on-Demand 
(Applied Biosystems) with Gusb and Actb as endogenous controls in hepatic and 
mammary tissues, respectively.   
 
Statistical analyses. All data analyses were performed using SAS 9.1.3 (Cary, 
NC).  The litter median of female progeny traits was used as the unit of TCDD analyses 
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to control for potential maternal exposure bias, although the result trends were identical 
when analyzing data from each pup individually or for litter means. Three litters (LFD + 
vehicle + vehicle, LFD +vehicle + DMBA, and HFD+TCDD+DMBA) had no females. 
Because of this imbalance in the design, the generalized linear model (Proc GLM) was 
used to evaluate the effect of these relationships on phenotypes (e.g. body weight, percent 
body fat, fasting blood glucose, branch elongation, fat pad length, number of terminal end 
buds, size of terminal end buds, and fold change of Cyp1a1, Cyp1a2, Cyp1b1, Areg, 
Ereg, Ahr, Egfr and Esr1 levels) (Livak and Schmittgen 2001). All Proc GLM analyses 
modeled phenotypes with additive main effects (TCDD, diet, DMBA) along with all two-
way interactions and the three-way interaction of the main effects.  Any significant 
interactions were explored with stratified analyses. Using the LSMEANS option of the 
Proc GLM, the multivariate geometric means were determined to be significantly 
different at unadjusted p < 0.05 across a limited number of a priori contrasts.  This 
conservative approach was taken because of small sample size and imbalance between 
some contrasts, e.g. fewer exposed to DMBA than vehicle.  
 
RESULTS 
 
Maternal TCDD exposure alters body composition and glucose of progeny. 
TCDD did not have any effects on either body mass or adiposity (data not shown), and 
because these measurements were made prior to DMBA exposure, body mass and 
adiposity were evaluated on individual mice to examine diet effects. HFD differentially 
influenced post-natal growth compared to LFD as early as PND 4 (p < 0.05, n = 27 and 
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31 mice respectively, Fig. 2-2A). Concordantly, pubertal D2 adiposity was 28.9% higher 
among those fed HFD (25.6%, n = 26 mice) relative to LFD (19.9%, n = 28 mice; p < 
0.001; Fig. 2-2B). Although D2 progeny weigh more and have more body fat on a HFD 
than LFD, HFD (n = 11 litters) did not significantly alter blood glucose compared to 
those progeny fed LFD (n = 10 litters). Yet among D2 on HFD, TCDD heightened 
fasting blood glucose 59.3% over vehicle-treated D2 (p < 0.05, n = 5 and 6 litters 
respectively, Fig. 2-2C).  
 
Pubertal mammary gland growth is suppressed in female progeny by maternal 
TCDD exposure. D2 pubertal mammary glands were analyzed for susceptibility to 
maternal TCDD exposure and diet (Fig. 2-3). TCDD significantly increased fat pad 
length relative to mammary glands from progeny of vehicle-treated dams (p < 0.05, n = 
11 and 10 litters respectively, Fig. 2-3A). Relative to maternal vehicle, TCDD 
significantly decreased branch elongation (p < 0.05, n = 10 and 11 litters respectively, 
Fig. 2-3B), the number of terminal end buds (p < 0.05, Fig. 3B), and the size of terminal 
end buds (p < 0.01, n = 10 and 11 litters respectively, Fig. 2-3C). Similar to maternal 
TCDD, pubertal DMBA exposure reduced the number of terminal end buds by 50% 
below the number of terminal end buds seen in vehicle exposed D2 (2.4 +/- 0.8 and 5.0 
+/- 0.6 respective means +/- SE, n = 10 and 11 litters respectively, p < 0.05, data not 
shown). This was the only DMBA effect seen in mammary glands. D2 females 
maintained on HFD showed significant increases in branch elongation and number of 
terminal end buds compared to those maintained on LFD (p < 0.01, n = 11 and 10 litters 
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respectively, Fig. 2-3B-C).  However relative to LFD (n = 10 litters), HFD (n = 11 litters) 
was not associated with any changes in terminal end buds size or fat pad length.  
Branch elongation and the number of terminal end buds were also modified by 
TCDD and dietary fat interactions. Among D2 maintained on HFD, maternal TCDD 
decreased branch elongation and the number of terminal end buds significantly less than 
vehicle- predicted by an additive model (p < 0.05, n =  5 and 6 litters respectively, Fig. 2-
3B-C). However among D2 maintained on LFD, maternal TCDD exposure had no 
different branch elongation and number of terminal end buds than vehicle (n = 6 and 4 
litters respectively, Fig. 2-3B-C).  
 
Pubertal hepatic Cyp1 expression is elevated by maternal TCDD exposure. 
Maternal TCDD (n = 11 litters) increased Cyp1a1 and Cyp1b1 mRNA at puberty relative 
to vehicle exposure (p < 0.01, n = 10 litters, Fig. 2-4A-B).  HFD increased Ahr 
expression significantly over LFD (p < 0.05, n = 11 and 10 litters respectively, Fig. 2-
5A).  DMBA and diet had no significant main additive effects on Cyp1b1, but they 
significantly interacted with each other. When D2 were maintained on HFD, DMBA 
significantly reduced Cyp1b1 induction relative to its vehicle (p < 0.05, n = 5 and 6 litters 
respectively, Fig. 2-5B). However, when D2 were maintained on LFD, DMBA had no 
effect on Cyp1b1 induction. These diet-dependent differences of Cyp1b1 induction were 
significant (p < 0.05, Fig. 2-5B). 
Increased Cyp1 induction is indicative of AhR activation. AhR, EGFR, and ER 
signaling pathways interact in mammary morphogenesis and carcinogenesis (Buters et al. 
1999; Ciarloni et al. 2007; Patel et al. 2006), However, no effects of developmental 
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chemical exposures or diet were observed on the expression of Areg, Ereg, Egfr, Esr1, 
Cyp1a1, or Cyp1b1 in D2 mammary glands (data not shown). 
 
DISCUSSION  
 
TCDD causes a broad range of toxic effects yet its mechanisms are only partially 
understood and likely dependent upon many variables such as dose, developmental stage 
of exposure, and possibly diet. In the present study we treated D2 with 1 µg/kg of TCDD, 
which is a very low dose in D2 (Poland and Glover 1980). We focused on two variables 
potentially affecting susceptibility to this early life TCDD exposure, DMBA and diet, 
since it is likely that an individual’s susceptibility to the effects of TCDD exposure is 
influenced by interactions with other environmental factors (Han et al. 2004b; Hakkak et 
al., 2007; Thomsen et al. 2006). 
Transient increases and decreases in body weight have been seen in rodents 
exposed to TCDD during gestation or adulthood, with typical- or high fat- diets 
(Desaulniers et al. 2001; Thiel et al. 1994; Zhu et al. 2008). Further, paternal exposure to 
Agent Orange had no effect on birth weight (Lawson et al. 2004), and we did not detect 
any transient or prolonged depression of body mass or fat due to 1 µg TCDD/kg dam 
exposure in D2.  
The amount of TCDD actually accumulated in the mammary gland of D2 mice on 
HFD is influenced by several findings. Increased adiposity slows TCDD elimination thus 
extending its T1/2 (DeVito et al. 2003; Michalek and Tripathi 1999). Also, the larger fat 
pads of HFD- and TCDD-exposed D2 sequester a higher cumulative dose of TCDD than 
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those on LFD (Hoppe and Carey 2007). The higher target-organ dosage and slower 
elimination of 1 µg TCDD/kg dam in D2 progeny on HFD may exceed the minimum 
TCDD dose required to activate signaling of the growing mammary epithelium. 
Maternal TCDD exposure and HFD interacted in a significantly non-additive 
manner on both fasting blood glucose and mammary development at puberty. HFD may 
have enhanced TCDD effects on glucose, branch elongation, and the number of terminal 
end buds. Alternatively, maternal TCDD could have enhanced HFD effects on fasting 
blood glucose while depressing HFD effects on mammary gland development. The 
simplest explanation is that HFD enhanced maternal TCDD effects through interaction on 
estrogen and its complex milieu of signaling. Evidence of TCDD depressing HFD diet 
effects on mammary toxicity is limited because the timing of exposure is so critical in 
endocrinology. TCDD is known to decrease adipogenesis in the high dose wasting 
syndrome (Phillips et al. 1995).  This could indirectly reduce HFD-induced precocious 
gland development, but here maternal TCDD did not significantly change adiposity of 
D2. Instead maternal TCDD increased the size of the fat pad.  
Obesity is frequently comorbid with type II diabetes. The risk of insulin 
resistance, incidence of type II diabetes, and diabetes-associated mortality are linked to 
low TCDD exposure in several epidemiological studies (Consonni et al. 2008; Cranmer 
et al. 2000; Henriksen et al. 1997). Only one study demonstrated an interaction between 
overweight and TCDD on type II diabetes risk (Fujiyoshi et al. 2006). Impaired glucose 
tolerance and adiposity are risk factors for type II diabetes in humans (Laspa et al. 2007). 
At 1 µg TCDD/kg dam, our impaired glucose tolerance data support the adiposity x 
TCDD interaction seen in Vietnam veterans (Fujiyoshi et al. 2006). It remains unclear 
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whether the interaction of HFD x maternal TCDD on fasting blood glucose reflects a 
TCDD- increase in HFD effects, or vice versa. The potential interaction of maternal 
TCDD and HFD on type II diabetes risk should be further investigated. 
The increase in fasting blood glucose due to maternal TCDD and diet together 
may also increase risk for aberrant puberty through hyperinsulineaemia. Pubertal 
hyperinsulineaemia is common but can persist into adult life (Stoll 1998). Normally 
during puberty insulin stimulates the synthesis of E2 in ovaries. The IGFR hormone 
pathway may further stimulate mammary growth through crosstalk with the ER hormone 
pathway (Stoll 1998). However, hyperinsulineaemia alters steroidogeneis in ovaries to 
change the E2 balance (Stoll 1998). Pubertal breast development is enhanced in 
overweight girls who eat diets high in polyunsaturated fats (Britton et al. 2004). 
Consistent with these observations, we found HFD caused precocious mammary 
development. Yet the precocious gland development was substantially reduced by both 
HFD and maternal TCDD exposure, in the same female offspring that had elevated 
fasting blood glucose. While this reduction in mammary growth was no further than that 
seen in vehicle treated D2 mice on LFD, gestational exposure to TCDD imprints on 
mammary gland morphology into adulthood (Fenton et al. 2002). This is consistent with 
delayed adolescent breast development seen correlated to increased serum TCDD levels 
in peripubertal girls (Den Hond et al. 2002). 
Estrogenic activity of adipose tissue also may be advancing the growth of the 
gland as well as enhancing signaling between the mammary epithelium, fat pad and 
TCDD (De Assis and Hilakivi-Clarke 2006). Consequently, adipose-dependent aromatase 
differences may be contributing to the mammary gland phenotypes we observed.  In a 
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higher adipose environment, there is greater aromatization of estrogen in peripheral 
adipose tissue such as mammary fat pads (Cheshenko et al. 2007; Lorincz and Sukumar 
2006; Simpson 2003).  TCDD can downregulate aromatase in a high E2 environment, yet 
will not alter aromatase levels at basal E2 levels (Cheshenko et al. 2007). Based on these 
findings, a HFD-dependent action of TCDD on mammary development could occur 
through direct and indirect actions of HFD and TCDD on aromatase.  
Ahr transcription is downregulated during adipogenesis (Shimba et al. 2003). The 
fact that basal Ahr was higher in D2 maintained on HFD indicates that elevation of Ahr 
expression is likely a consequence of weight gain, and not a casual mechanism.  AHR 
signaling involves crosstalk with ERα and EGFR, receptors that are upregulated in 
overweight individuals (Lorincz and Sukumar 2006; Moral et al. 2003).  Each of these 
AHR-mediated signaling pathways also interacts with mammary morphogenesis during 
puberty (Howlin et al. 2006).  Although several groups demonstrated a role for EGFR 
and its ligands in both mammary morphogenesis and in AHR-mediated TCDD activity 
(Ciarloni et al. 2007; Howlin et al. 2006; Patel et al. 2006), we found no change in Esr1, 
Egfr or the EGFR ligand genes Areg and Ereg in the mammary gland.    
In addition to cross talk with E2-mediated pathways, AHR facilitates Cyp1a1 and 
Cyp1b1 induction by TCDD. While neither Cyp1a1 nor Cyp1b1 was altered in the 
mammary gland, at 1 µg TCDD/kg dam we saw a modest increase in D2 hepatic Cyp1a1 
and Cyp1b1 progeny at puberty. While this may not translate to changes in protein 
activity, TCDD may be altering the metabolism of DMBA and E2. Because D2 are non-
responsive to PAH induction, without this maternal TCDD exposure, DMBA would not 
be metabolically activated (Chapman and Schiller 1985; Moriguchi et al. 2003). 
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However, if increased Cyp1a1 and Cyp1b1 message by maternal TCDD translates to their 
increased protein activity, DMBA could be metabolically activated (Chapman and 
Schiller 1985; Moriguchi et al. 2003). This implies that maternal exposure to TCDD 
could cause DMBA-induced mammary carcinogenesis in mice not typically susceptible 
to DMBA-induced mammary carcinogenesis. 
Maternal TCDD could indirectly decrease E2 by increasing its metabolism. In the 
liver and mammary glands, CYPA1A1 and CYP1B1 generate the catechols 2-
hydroxyestradiol (2OH-E2) and 4-hydroxyestradiol (4OH-E2) from E2, respectively 
(Tsuchiya et al. 2005). Recent evidence suggests that TCDD-stimulated production of 
these catechols is increased further in mice fed HFD (Zhu et al. 2008). By increasing 
body weight gain and adiposity, HFD can indirectly contribute to increased number of 
terminal end buds, local E2, and mammary tumor incidence (Hakkak et al. 2007; 
Hilakivi-Clarke et al. 1997; Mizukami et al. 1992). It may be that upregulation of hepatic 
Cyp1a1 and Cyp1b1by maternal TCDD reduces the levels of E2 in the mammary gland, 
especially in mice fed HFD. Increased estrogen metabolism and less E2 may be a 
mechanism of TCDD-decreased mammary growth (Ciarloni et al. 2007; Howlin et al. 
2006) and cancer risk (Zhu et al. 2008) in adult mice. 
While maternal TCDD could reduce E2 levels and thus decrease risk of mammary 
cancer, upregulation of Cyp1a1 and Cyp1b1 in female progeny by 1 µg TCDD/kg dam 
may also increase risk of mammary carcinogenesis. If increased CYP1A1 and CYP1B1 
levels are not met with concurrent increases in other E2-metabolizing enzymes, 
mutagenic-E2 metabolites may increase breast cancer risk (Cavalieri and Rogan 2004; 
Cavalieri et al. 1997). Upregulation of Cyp1a1 and Cyp1b1 in female progeny by 
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maternal TCDD may also increase risk of mammary carcinogenesis through interaction 
with pubertal DMBA exposure. CYP1A1 genotype-stratified analyses demonstrate a 
stronger association between exogenous AHR ligands and breast cancer when CYP1A1 
is more active (Ambrosone et al. 1995; Li et al. 2005a).  This hypothesis is consistent 
with the increased susceptibility to DMBA-carcinogenesis in rats after perinatal TCDD 
exposure (Brown et al. 1998; Desaulniers et al. 2004).  
 Since delayed breast development is closely associated with delayed menarche, a 
well-known protection against breast cancer (Kadlubar et al. 2003), one might expect 
delayed or slowed breast differentiation to protect against breast cancer. Yet evidence 
suggests that by disrupting mammary gland differentiation, early TCDD exposure 
extends the period that mammary glands are most susceptible to mutagenic insults 
(Birnbaum and Fenton 2003; Brown et al. 1998; Desaulniers et al. 2001; Fenton et al. 
2002). In humans, rats, and now mice, evidence supports that some prepubertal TCDD 
exposures may delay mammary differentiation and enhance susceptibility to adult 
mammary carcinogenesis.  
We saw a similar apparent delay in differentiation with DMBA treatment.  
Mammary tumors are correlated with the number of terminal end buds at the time of 
DMBA dosing (Russo and Russo 1978). If this DMBA is the only pubertal exposure in 
female progeny, TCDD-decreased number of terminal end buds may protect them from 
breast cancer.  If they are exposed again, or perhaps chronically, it may increase risk of 
breast cancer (Birnbaum and Fenton 2003; Brown et al. 1998; Desaulniers et al. 2001). 
The potential interaction of maternal TCDD and HFD on the risk of mammary cancer in 
female progeny should be further investigated. 
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DMBA and TCDD represent PAHs and PHAHs, respectively, that are ubiquitous 
chemicals in the environment, and that frequently occur as mixtures in human and 
environmental samples. Because of the prevalence of TCDD exposure and elevated 
adiposity in humans, it is likely that everyone has some TCDD tissue burden. Women 
that have been exposed to TCDD may transfer TCDD to their children through 
maternofetal transfer and breast feeding, further increasing the risk of exposure to 
environmental mediators of breast cancer during developmental windows of 
susceptibility. As this study reports the third species to show TCDD inhibition of pubertal 
mammary growth, reduced mammary development in female progeny may be a 
generalized effect of maternal TCDD exposure.  
 
FIGURE LEGENDS 
 
Figure 2-1. Schematic diagram of treatment groups (top) and timeline (bottom). 
Impregnated D2 mice were treated with 1 µg/µl TCDD or 95%/% olive oil/toluene 
(vehicle) at 12.5 days post coitus. Litters were put on HFD or LFD at PND 0 and weaned 
at PND 21 continuing on same diets.  On PND 35, mice were treated with 60 mg/kg 
DMBA or vehicle, fasted, weighed, and measured for percent body fat.  Twenty-four 
hours later, blood glucose was measured and inguinal mammary and median liver lobes 
harvested. 
 
Figure 2-2. Diet and maternal TCDD exposure effects metabolic phenotypes. (A) The 
effect of diet on post-natal D2 body weights. Symbols represent means +/- SEM, where 
at PND 4 and later, * indicates p < 0.05 between diets. D2 ranged from 27 and 31 mice at 
PND 0 to 26 and 28 mice at PND 35 for HFD and LFD respectively. (B) HFD (n = 26 
mice) increases percent fat at PND 35 relative to LFD (n = 28 mice), where * indicates p 
< 0.0001. (C) Fasting blood glucose is increased by HFD and maternal TCDD (strips) in 
female progeny at PND 36.  Vehicle is solid, Means +/- SEM, where * indicates p < 0.05 
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for HFD and vehicle (n = 6 litters) vs. HFD + TCDD (n = 5 litters). Because diet, but not 
TCDD, changed body weight and percent body fat, these analyses were done on 
individual mice. 
 
Figure 2-3. Mammary gland morphology is altered by maternal TCDD and HFD. 
Inguinal mammary whole mounts were made of glands removed from vehicle- and 
TCDD- treated D2 on HFD or LFD at PND 36.   Whole mounts were stained with 
carmine alum, blinded, and measured for (A) fat pad length, (B) branch elongation, (C) # 
of terminal end buds, and (D) largest terminal end bud. Means +/- SEM are shown for 
LFD and vehicle (n = 4 litters), LFD and TCDD (n = 6 litters, strips), HFD and vehicle (n 
= 6 litters), HFD and TCDD (n = 5 litters, strips) treatment groups.  Significant diet- and 
TCDD x diet-effects are distinguished by * p < 0.05. 
 
Figure 2-4. Maternal TCDD significantly increases pubertal hepatic Cyp1 message. RNA 
was extracted from median liver lobes.  Messages were assessed using quantitative real 
time PCR, with Gusb as an endogenous control. Means +/- SEM are shown, where levels 
are distinguished by p < 0.01. (A) Induction of Cyp1a1 message by TCDD compared to 
vehicle (n = 11 and 10 litters respectively), pooled across diet and DMBA groups. (B) 
Induction of Cyp1b1 messages by TCDD compared to vehicle (n= 11 and 10 litters 
respectively), pooled across diet and DMBA groups.  
 
Figure 2-5. Diet and DMBA significantly alter hepatic gene expression. RNA was 
extracted from median liver lobes.  Messages were assessed using quantitative real time 
PCR, with Gusb as an endogenous control. Means +/- SEM are shown, where levels are 
distinguished by * p < 0.05. (A) Induction of Ahr message is increased by HFD relative 
to LFD (n = 11 and 10 litters respectively), pooled across TCDD and DMBA groups.  (B) 
Induction of Cyp1b1 message by DMBA decreases below vehicle in HFD-, but not LFD- 
fed D2, where groups are LFD and vehicle (n = 5 litters), LFD and DMBA (n = 5 litters), 
HFD and vehicle (n = 6 litters), HFD and DMBA (n = 5 litters) treatment groups. 
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CHAPTER 3 
 
MOUSE BREAST CANCER-MODEL DEPENDENT CHANGES IN 
METABOLIC SYNDROME-ASSOCIATED PHENOTYPES CAUSED BY 
MATERNAL TCDD EXPOSURE AND DIETARY FAT1 
 
ABSTRACT 
 
Diets high in fat are associated with increased susceptibility to obesity and metabolic 
syndrome. Increased adipose tissue caused by high fat diets (HFD) may result in altered 
storage of lipophilic toxicants like 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 
susceptibility to cancer. Since both TCDD and HFD are associated with increased breast 
cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in 
three mouse models of breast cancer: 7,12-dimethylbenz[a]anthracene (DMBA), 
Tg(MMTV-Neu)202Mul/J (HER2) and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an 
FVB/N genetic background.  Pregnant mice were dosed with 1 µg/kg of TCDD or vehicle 
on gestational day 12.5, and at parturition placed on HFD or low fat diet (LFD).  Body 
weights, percent body fat, and fasting blood glucose were measured longitudinally, and 
triglycerides were measured at study termination. All cancer models reached the pubertal 
                                                
1 David S. Baston preformed nuclear receptor assays. 
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growth spurt ahead of FVB controls. From puberty through adulthood, the HER2 model 
had increased body weight and adipose tissue compared to PyMT and DMBA. However, 
the DMBA model consistently had higher fasting blood glucose levels than PyMT and 
HER2. TCDD only impacted serum triglycerides in the PyMT model maintained on 
HFD. Since the estrogenic activity of the HFD was three times lower than that of the 
LFD, differential estrogenic activities did not drive the observed phenotypic differences. 
Rather, the HFD-dependent changes were cancer-model dependent.  
 
INTRODUCTION 
 
Metabolic syndrome represents a constellation of disease-associated physiological 
changes affecting over 47 million US residents (Ford et al. 2002). The key etiological 
component of metabolic syndrome is obesity, which can promote insulin insensitivity and 
type II diabetes.  Additionally, excess adipose tissue results in increased storage of fatty 
acids and triglycerides in peripheral tissues (Roche et al. 2005).  Abundant adipose tissue 
also causes excess endocrine signaling that increases insulin insensitivity and estrogen 
aromatization, which in turn increases adipose proliferation, body weight and fasting 
blood glucose insensitivity (Bunt 1990; Mayes and Watson 2004; Trayhurn and Wood 
2004; Vidal et al. 1999). Peripheral estrogen aromatization by excess adipose tissue is 
also thought to contribute to the increased post-menopausal breast cancer risk among 
obese women (Hakkak et al. 2007; Simpson 2003). 
Individuals that have metabolic syndrome or that are obese usually have higher 
consumption of fatty foods from animal origin, which is associated with a greater body 
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burden of lipophilic endocrine disruptors such as 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) (Harrad et al. 2003; Hayward et al. 1999; Hooper et al. 1998; Muntean et al. 
2003). Elimination of TCDD is slowed substantially as body fat increases (Emond et al. 
2006; Michalek and Tripathi 1999). Consequently, obese individuals may have unique 
susceptibilities to the effects of TCDD and other lipophilic endocrine disruptors. 
Although the effects of high doses of TCDD are a depletion of both lean and 
adipose tissue that results in a wasting syndrome(Pohjanvirta and Tuomisto 1994), the 
effects of low doses of TCDD seem to shift away from body compositional changes to 
endocrine disruption and promotion of diseases associated with metabolic syndrome like 
type II diabetes. Human exposure to TCDD has resulted in an increase in serum insulin 
levels, diabetes, diabetes-associated mortality in females and an earlier diabetes onset 
(Consonni et al. 2008; Cranmer et al. 2000; Henriksen et al. 1997).  
While there is evidence that TCDD exposure and diets high in fat (HFD) interact 
and effect metabolic syndrome, little is known about how these exposures impact breast 
cancer. Breast cancers can be partitioned into distinct subtypes that represent unique 
histopathologies, genetic alterations, treatment responses and perhaps risk factors 
(Herschkowitz et al. 2007). Because of human breast cancer diversity, multiple mouse 
models have been used to recapitulate clinically significant aspects of initiation, 
progression and invasion.   
Two human breast cancer subtypes are estrogen receptor (ER)-negative with poor 
prognosis (Sorlie et al. 2001; Sorlie et al. 2003). One of these subtypes has 
basal/myoepthilial cell characteristics (basal-like). Basal-like subtypes represent 5-10% 
of breast cancers and include those with BRCA1 and HRAS mutations (Herschkowitz et 
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al. 2007), which are involved in proliferation and invasion (Moon 2006).  The other ER-
negative breast cancer subtype has high ERBB2 (HER2) expression and is associated 
with reduced patient survival (Witton et al. 2003). Similar to these human breast cancers, 
the 7,12-dimethylbenz[a]anthracene (DMBA) carcinogen-induced mouse model of breast 
cancer results in hyperactivation of Hras and heightened proliferation (Cardiff et al. 
1988; Herschkowitz et al. 2007).  Luminal-type breast cancers represent a third subtype, 
and prognosis for these can be good (luminal A) or bad (luminal B) (Sorlie et al. 2001; 
Sorlie et al. 2003).  The PyMT transgenic mouse model has characteristics of the luminal 
subtype of breast cancer (Herschkowitz et al. 2007).  
To elucidate consequences of the interaction between dietary fat and TCDD 
exposure on metabolic syndrome-associated phenotypes in different breast cancer 
subtypes, three mouse distinct models of breast cancer were exposed maternally to low-
dose TCDD in combination with either a HFD or a lower-fat, matched control diet 
(LFD). To directly compare metabolic syndrome-associated phenotypes across different 
cancer types, all three models were maintained on a uniform FVB/NJ genetic 
background, which is susceptible to TCDD toxicity and diet-induced obesity (Cleary et 
al. 2004; Hakkak et al. 2007; Jones et al. 1991; Luijten et al. 2004; Martin et al. 2006).  
 
MATERIALS AND METHODS 
 
Chemicals. DMBA (98% pure), 17β-estradiol (98% pure E2), and 5-alpha-
androstan-17beta-OL-3-one (99% pure DHT) were purchased from Sigma-Aldrich (St. 
Louis, MO). TCDD was purchased from Ultra Scientific (99.9% pure, North Kingstown, 
44 
RI). DMBA and TCDD were dissolved in 95%/5% olive oil/toluene by volume (Certified 
ACS, Sigma-Aldrich, St. Louis, MO), and used at 25 mg/ml and 0.5 ng/µl stock 
concentrations, respectively. Dosing was at 2.4 µl DMBA solution/g mouse and 1.8-1.9 
µl TCDD solution/g mouse. In the diet activity assays, TCDD, E2 and DHT were 
dissolved in dimethyl sulfoxide (DMSO, Certified ACS, Fisher Scientific, Pittsburg, PA) 
and activity levels determined as described below. 
 
Diets. Mice were fed a HFD (4.73 kcal/g, D12451, Research Diets, New 
Brunswick, NJ) composed of 20% protein, 35% carbohydrate, and 45% fat by total kcal 
or a LFD (3.85 kcal/g, D12450B, Research Diets) composed of 20% protein, 70% 
carbohydrate, and 10% fat by total kcal.  The primary differences between the matched 
diets are increased maltodextrin and lard, and decreased cornstarch and sucrose in the 
HFD compared to the LFD (400, 1598, 291, 691 kcal vs. 140, 180, 1260, 1400 kcal, 
respectively).  The LFD has fat levels that fall within the range commonly found in 
standard rodent chows, but much lower than the typical human diet in the United States.  
 
 Mice and husbandry. Females from three mouse models of breast cancer, all on 
the FVB/NJ (FVB) background, were used. Nulliparous female FVB mice were mated 
with male homozygous FVB-Tg(MMTVNeu)202Mul/J mice (Jackson Laboratories, Bar 
Harbor, ME) to generate female pups for the HER2 model, representing ER-negative, 
HER2-positive breast cancers (Herschkowitz et al. 2007; Weinstein et al. 2000). 
Nulliparous female FVB and male homozygous FVB-TgN(MMTV-PyMT)634Mul/J 
(NCI MMHCC Repository, Frederick, MD) mice were crossed to generate female 
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offspring for the PyMT model, representing ER-negative luminal breast cancers (Guy et 
al. 1992; Herschkowitz et al. 2007; Qiu et al. 2004). Nulliparous female and male FVB 
mice were mated to produce female pups used in the DMBA model, representing basal-
like breast cancers (Herschkowitz et al. 2007), as well as untreated FVB controls. , Six 
litters per treatment were used for the DMBA model because of the added variability 
associated with carcinogen models, while three litters were used for the Her2 and PyMT 
models and FVB controls. 
Heterozygous PyMT mice were identified using primers 5’-
AACGGCGGAGCGAGGAACTG and 5’-ATCGGGCTCAGCAACACAAG (Operon, 
Huntsville, AL) and a PCR protocol previously described (Jackson Laboratories, Bar 
Harbor, ME;(Laboratories 2008). Heterozygous HER2 mice were identified using PCR 
primers 5’-TTTCCTGCAGCAGCCTACGC and 5’-CGGAACCCACATCAGGCC (Qiu 
et al. 2004). Mice were housed in HEPA-filtered ventilated cages with food and water 
provided ad libitum. Care and treatment of the mice complied with the guidelines of the 
Animal Welfare Act under an Institutional Animal Care and Use Committee (IUCAC)-
approved protocol. Carbon dioxide asphyxiation euthanasia was performed on mice that 
developed tumor of one cm in diameter or at 11 months of age, whichever came first. 
FVB control mice were euthanized by carbon dioxide asphyxiation at post-natal day 
(PND) 121. 
 
 Treatment and experimental groups. The effects of diet and TCDD were studied 
in a randomized 2 x 2 factorial design (Fig. 3-1). Noon on the day when females, housed 
with males representing one of the three breast cancer models, were observed with a 
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vaginal plug was designated at 0.5 days post coitus (dpc). On 12.5 dpc, 1 µg/kg of TCDD 
was administered by oral gavage to pregnant FVB (n = 12), PyMT (n = 6) and HER2 (n = 
3) dams, or the equivalent volume of vehicle to pregnant FVB (n = 18) and PyMT (n = 6) 
dams. From parturition (PND 0), dams were fed one of the two standardized diets, and 
their respective pups were weaned at PND 21 onto the same diet until euthanasia. FVB 
and PyMT litters were assigned to HFD or LFD symmetrically with respect to TCDD 
exposure status, while HER2 litters from TCDD-exposed dams were assigned to HFD 
only. In total, 30 FVB, 12 PyMT and six HER2 litters were fed HFD or LFD. Litters 
were culled to four mice at PND 4, maximizing the number of females with the desired 
genotype. At PND 35, 49 and 63, 60 mg/kg of DMBA was administered by oral gavage 
to 24 FVB litters.  The remaining six FVB litters served as controls. DMBA and HER2 
mice were palpated weekly for tumors beginning at PND 83; PyMT mice were palpated 
for tumors three times per week beginning at PND 35.   
 
 Body composition. At PND 0, body mass was determined by dividing the total 
litter mass by the number of pups within the litter. Individual body masses were 
evaluated at PND 4, 7, 10, 14, 21, 35, 49, 63, 90, 120, 150, 180, 210, 240, 270, 300 and 
330. At PND 35, 90 and 180, all mice were placed under isoflourane anesthesia for 
approximately five minutes while undergoing dual energy x-ray absorptiometry (DEXA; 
GE Lunar PIXImus Corp., Madison, WI) to evaluate percent body fat.  
 
 Blood chemistry. Following a 24-hour fast at PND 35, 120, 180, 240 and 300, 
blood glucose levels were measured using a ThermaSense FreeStyle blood glucose kit 
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(Alameda, CA). Immediately following euthanasia, blood was drawn from the inferior 
vena cava and serum stored at -80°C for triglyceride analysis using StanBio Laboratories 
Enzymatic Triglycerides Procedure 2150 (Boerne, TX). 
 
 Nuclear receptor activity assays. Approximately 10 g of each diet were crushed 
with a mortar and pestle, and extracted three times with 20 ml of toluene (non-polar 
extract) or ethanol (polar extract). The extract was allowed to settle before passing the 
supernatant through a Celite filter column. The column was rinsed with 20 ml of toluene 
or ethanol.  The toluene or ethanol extracts were dried and resuspended in 4 ml of the 
same solvent.  Aliquots of polar (200 µl) and non-polar (300 µl) suspensions were mixed 
with 3.5 µl of DMSO, and the solvents were removed by vacuum centrifugation before 
the remaining DMSO was mixed with 350 µl of culture media.  Each diet extract was 
analyzed for its ability to activate expression of an estrogen receptor (ER), androgen 
receptor (AR) or aryl hydrocarbon receptor (AhR)-dependent firefly luciferase reporter 
gene in stably transfected human ovarian (BG1), human breast cancer (T47D) and mouse 
hepatoma (Hepa1c1c7) cell lines, respectively (Han et al. 2004a; Rogers and Denison 
2002; Ziccardi et al. 2000).  
Concentration-dependent reporter gene induction was determined by analysis of 
the inducing potency of a serial dilution of each sample extract (100 µl/well). Cells 
(75,000) were plated into sterile COSTAR white clear-bottomed 96-well tissue culture 
microplates (Corning Inc., Corning NY) and allowed to attach for 24 hr prior to chemical 
treatment. For the ER bioassay, cells were maintained in estrogen-stripped media for 5 
days before plating to reduce background estrogen activity. Cells were incubated with 
48 
diet extracts, carrier DMSO solvent (1% final solvent concentration) or increasing 
concentrations of E2, DHT or TCDD standards for 24 hr at 37ºC.  After 24 hr of 
incubation, all microplate wells were washed twice with phosphate-buffered saline before 
adding of 50 µl of cell lysis buffer (Promega Inc., Madison, WI) and shaking for 20 min 
at room temperature to facilitate cell lysis. The plates were inserted into a Berthold 
microplate luminometer (Spectranalyzed Berthold Detection Systems, Bleichstrasse 56-
68, Pforzheim, Germany), and luciferase activity in each well was measured, integrated 
over 10 sec after a 2 sec delay, following automatic injection of 50 µl Promega stabilized 
luciferase reagent (Ziccardi et al., 2000; Rogers et al., 2000; (Han et al. 2004a).  
Luciferase activity in each well was expressed relative to the maximal inducing 
concentration of the respective positive control (E2, DHT or TCDD). 
 
 Statistical analysis. All statistical analyses were performed with SAS software, 
version 9.0 (SAS Institute, Cary, NC). Monophasic and diphasic sigmoidal models of 
change in body mass over time were evaluated for all cancer models and controls 
according to (1) using PROC NLIN (Koops 1986; Koops et al. 1987):  
yt = ∑i [ai {1 + tanh (bi (t – ci))}]    
 (1) 
where yt is the predicted body weight (g) at age t, i is the number of phases, ai is half the 
asymptotic value of y in phase i, bi is a growth parameter in phase i, and c1 is the age at 
the inflection point of phase i.  It follows that when i = 1, parameters a1, b1 and c1 
describe growth in prepubertal mice and when i = 2, parameters a2, b2 and c2 describe 
growth in postpubertal mice. a1 is the body weight (g) at the maximum prepubertal 
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growth rate, 2a1 + a2 is the body weight (g) at the maximum postpubertal growth rate, aib1 
is the maximum prepubertal growth rate (g/PND), a2b2 is the maximum postpubertal 
growth rate (g/PND), c1 is the age at the maximum prepubertal growth rate (PND), and c2 
is the age at the maximum postpubertal growth rate (PND).  
Changes in fasting blood glucose and percent body fat over time were modeled 
longitudinally with PROC MIXED. Because pregnant dams were exposed to TCDD, the 
litter was used as a random effect. Median triglycerides per litter were evaluated using 
ANOVA and student’s two-way t-test for all pairwise comparisons at an alpha level of 
0.05.   
For nuclear receptor activity assays, mean relative light units were determined at 
each concentration in both toluene and ethanol extracts for standard and diet samples. 
From this, the effective extract concentration giving 50% of the maximal induction 
response was calculated (EC50) for each standard in both toluene and ethanol extracts. 
The percent effective concentration (EC[x]) of each diet was then determined in both 
toluene and ethanol extracts. ANOVA was used to assess significance of induction 
equivalents, as a ratio of the ECx value of the sample and the equivalent value from the 
standard curves, between diet samples for each standard and solvent combination. 
 
RESULTS 
 
 HFD increases longitudinal body weight. The effect of dietary fat on body weight 
was determined by analyzing the interaction between body weight and age using 
individual mice.  HFD increased the body weight and growth of mice from the DMBA 
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and PyMT models, but not of FVB control mice. Since mice from the HER2 model were 
only raised on HFD, no diet comparisons were performed with this model. Neither 
TCDD nor tumor presence had an effect on body weight for any model.  
For mice from the DMBA model, the diphasic sigmoidal model of growth fit best 
(R2 = 0.945) (Koops et al. 1987). At prepubertal time points before DMBA treatment, 
HFD increased the maximum growth rate and decreased the age at the maximum growth 
rate of mice from the DMBA model as compared to LFD (p < 0.01, Fig. 3-2a, Table 1). 
Similarly, HFD also increased the maximum growth rate of mice from the DMBA model 
at postpubertal time points as well as the weight at the maximum growth rate (p < 0.001). 
DMBA mice maintained on HFD had higher body weights compared to mice maintained 
on LFD from PND 4 until PND 300, when there were insufficient mice on HFD still 
surviving for comparison (p < 0.01).  
The monophasic sigmoidal model of growth fit best for mice from the PyMT 
model (R2 = 0.989) (Koops et al. 1987).  Similar to mice from the DMBA model, 
prepubertal PyMT mice maintained on HFD had a faster maximum growth rate at a 
younger age than those maintained on LFD (p < 0.01 and 0.05, respectively; Fig. 3-3a, 
Table 2). Mice from the PyMT model maintained on HFD were also heavier at the 
maximum growth rate than those maintained on LFD (p < 0.05); there was a trend of 
increased body weight with HFD in PyMT model across all ages, though it was only 
significant between PND 14 and 35 (p < 0.05).   
 
 HFD increases longitudinal percent body fat. The effect of dietary fat on percent 
body fat was analyzed as an interaction between diet and PND for individual mice over 
51 
time with litter as a mixed effect. Similar to body weight, neither perinatal TCDD nor 
tumor presence caused a change in percent body fat. 
Percent body fat was greater in mice from the DMBA model maintained on HFD 
compared to those maintained on LFD at all ages measured (p  < 0.01, Fig. 3-2b), with 
the effect of HFD becoming more pronounced with aging (p < 0.0001). This trend was 
similar to that seen for the PyMT model, where percent body fat increased with time in 
mice maintained on HFD but not on LFD, causing a significant dietary-induced 
difference in percent body fat by PND 90 (p < 0.05, Fig. 3b). Relative to LFD, 
maintenance on HFD resulted in increased percent body fat in FVB control mice at PND 
35 (p = 0.05) but not at PND 90 (data not shown). Unlike mice from the DMBA and 
PyMT breast cancer models, control FVB mice were resistant to diet-induced adiposity. 
 
 HFD increases longitudinal fasting blood glucose. Fasting blood glucose was 
modeled as an interaction between dietary fat and PND on individual mice using litter as 
a mixed effect.  Consistent with elevated percent body fat, fasting blood glucose was 
significantly elevated in mice from the DMBA model maintained on HFD compared to 
those on LFD at all ages after PND 35 (p < 0.05). This difference between the effects of 
diet increased with age (p < 0.0001, Fig. 2c). Fasting blood glucose was not affected by 
diet in FVB control mice at PND 35 or 120 (data not shown), nor in the PyMT cancer 
model mice at PND 35 (Fig. 3c).  Later time points were not evaluated in the PyMT 
cancer model mice due to the aggressive nature of the tumors in this model (mean age at 
death = PND 65).  
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 HFD and TCDD depress serum triglycerides. Unlike body fat and fasting blood 
glucose, serum triglycerides were affected by TCDD, thus ANOVAs were performed on 
the medians of litter triglyceride values. Dietary fat and TCDD had no effect on 
triglycerides in mice from the DMBA model or FVB control mice (Fig. 2d).  However, 
triglycerides were significantly depressed in mice from the PyMT model by a combined 
exposure of HFD and TCDD (p < 0.01, Fig. 3d).  
 
 Differences among models in the longitudinal effects of HFD. Mice from the 
DMBA and PyMT breast cancer models had faster maximum prepubertal growth rates 
than FVB control mice (p < 0.05, Table 3). Mice from the DMBA and HER2 models 
weighed the least and most, respectively, at their maximum prepubertal growth rates, 
possibly reflecting differences in their age of maximum prepubertal growth rate (Table 
3). FVB control mice reached their maximum prepubertal growth rate later than mice 
from the breast cancer models .  By PND 35, and continuing through adulthood at PND 
180, mice from the HER2 model were heavier than all others (p < 0.01, Table 4). After 
PND 180, there was no difference between weights or growth trajectories of mice from 
the HER2 and DMBA models.   
 Trends for percent body fat in the three models of breast cancer were similar to 
trends in body mass.  Mice from the HER2 model had a higher percent body fat early in 
life than mice from the DMBA and PyMT models, or FVB control mice (p < 0.01), but 
by PND 180 percent body fat was similar between mice from the DMBA and HER2 
models (Table 4). Percent body fat did not differ at any age among mice from the DMBA 
and PyMT models, or the FVB control mice. 
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Mice from the DMBA model had higher fasting blood glucose than those from 
the PyMT and HER2 models at PND 35 (p < 0.05, Table 4). However, by PND 120 mice 
from both the DMBA model and FVB control had higher fasting blood glucose than 
those from the HER2 model (p < 0.05).  This divergence increased throughout the 
duration of the study. Mice from the HER2 model maintained constant levels of fasting 
blood glucose over time, while mice from the DMBA model continued to increase until 
PND 300. There were no differences among the models of breast cancer or controls in 
their serum triglyceride levels, despite differences in age at euthanasia (Table 4). 
 
 LFD has higher nuclear receptor activity than HFD. Differences between the 
HFD and LFD with regards to the presence of endocrine disrupting chemicals could 
underlie their differential effects on metabolic syndrome-associated phenotypes (Thigpen 
et al. 2004).  Accordingly, both diets were analyzed for their ability to activate ER, AR or 
AhR using luciferase reporter gene assays.  Dose-response studies revealed that little or 
no AR- or AhR-dependent reporter gene expression was observed using polar and non-
polar extracts from either diet (data not shown).  In contrast, significant induction of ER-
dependent reporter gene expression was observed using non-polar extracts from both 
diets (Table 5); little or no ER-dependent activity was observed using polar extracts.  
Comparison of ER-dependent reporter gene expression levels using dose-response 
analysis revealed that the overall estrogenic activity of the LFD was three times greater 
than that of the HFD (p < 0.01), counter to that expected if differences in diet-derived 
estrogenic activities were responsible for the metabolic syndrome-associated phenotype 
differences. 
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DISCUSSION 
 
Metabolic syndrome and breast cancer are traits with complex etiologies driven in 
part by disrupted endocrine signaling.  With the increasing prevalence of metabolic 
syndrome in humans, it is critical to characterize the susceptibility of those with 
metabolic syndrome to environmental endocrine disruptors and to cancer.  Through a 
cross-model comparison using three mouse models of breast cancer on a uniform genetic 
background, we have provided insights into the contribution of different breast cancers to 
diet induced-metabolic syndrome-associated phenotypes.  
 
Body composition. We observed age-dependent differences in percent body fat 
due to diet in all three models of breast cancer and the FVB controls, consistent with 
reports that DMBA, PyMT,and HER2 are sensitive to dietary fat and obesity (Gordon et 
al. 2008; Hakkak et al. 2007; Luijten et al. 2004).  
The body weight and fat accumulation seen in the HER2 model, relative to all 
other mice, may be due to the biology of the model (Koops and Grossman 1991).  HER2 
is part of the receptor family involved in the MAPK proliferation pathway, and 
overexpression of HER2 may lead to greater mammary adiposity. Consistent with a link 
between HER2 and obesity, women with HER2-positive breast cancer are more likely to 
be overweight/obese than women without cancer (Jones et al. 2007). The increased 
adiposity in the HER2 model is also supported by results showing that higher ERBB2 
(HER2) activity levels decrease preadipocyte differentiation, which is permissive of 
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clonal adipocyte expansion (Harrington et al. 2007). Since low transcript levels of the 
HER2 transgene have been detected in the thymus, it is also possible that the adiposity of 
this model was driven by thymic endocrine changes (Huang et al. 2003; Savino 2007).   
Fasting blood glucose. We observed a general resistance to dietary effects on 
fasting blood glucose levels among the transgenic models of breast cancer. The PyMT 
and HER2 models as well as the FVB controls were resistant to HFD-induction of 
elevated blood glucose levels. In contrast, the DMBA model appeared to develop 
impaired glucose tolerance, a risk factor of both metabolic syndrome and type II diabetes 
(2001), in response to HFD.  
The variation in fasting blood glucose levels among cancer models demonstrates 
the independent etiologies of their metabolic syndrome phenotypes. The HER2 model 
had greater adiposity than the DMBA model, yet the converse is true with respect to 
fasting blood glucose levels. These two metabolic syndrome-associated phenotypes are 
typically highly correlated (Eberhardt et al. 2004).   
 
TCDD. Exposure to TCDD exposure in humans is associated with an increased 
risk for diseases linked to metabolic syndrome like type II diabetes. However, there are 
yet no animal models for low dose TCDD-associated changes in disease risk. Our results 
are consistent with previous observations that the TCDD wasting syndrome is only a high 
dose phenomena since we did not detect any influence of maternal TCDD exposure on 
longitudinal changes in body mass, percent body fat or fasting blood glucose. The only 
exception was serum triglycerides. 
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Triglycerides. Our low dose TCDD results clarify previous conflicting reports and 
suggest that serum triglycerides are decreased by acute TCDD exposure (Birnbaum et al. 
1990; Chapman and Schiller 1985; Pelclova et al. 2001; Sweeney and Mocarelli 2000). 
We also found that increased dietary fat increases susceptibility to TCDD-induced 
changes in triglycerides. Interestingly, the interaction between dietary fat and TCDD on 
triglycerides was only observed with the PuMT model, underscoring the importance of 
defining susceptibility in terms of specific gene-by-environment interactions. 
 
Summary. Here we show that three mouse models of breast cancer, driven by 
specific oncogenes or induced by a carcinogen, can differentially impact the presentation 
of metabolic syndrome-associated phenotypes. Exposure to HFD caused variation in 
metabolic syndrome-associated phenotypes among these widely used mouse models.  In 
the DMBA model, HFD caused a modest change in body fat but a large change in fasting 
glucose level.  Conversely, HFD in the HER2 model resulted in a large change in body 
fat without changing fasting glucose levels.  In the PyMT model, HFD caused a large 
change in body fat and triglycerides without changing fasting glucose levels. The 
variation observed among different mouse models of breast cancer in response to HFD 
and maternal TCDD exposure may have utility in elucidating of the mechanisms of those 
metabolic syndrome-associated phenotypes that are etiologically linked to breast cancer 
risk.    
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Table 3-1. Effects of dietary fat on body growth characteristics in the DMBA model. 
Growth 
phase 
Parameter Interpretation LFD HFD 
1 a1 Weight at maximum growth rate (g) 11.0 (0.27) 10.7 (0.45) 
1 a1 x b1 Maximum growth rate (g/PND) 0.640 (0.02) 0.730 (0.02) 
1 d1 Age at maximum growth rate (PND) 18.8 (0.35) 16.7 (0.29) 
2 2a1 + a2 Weight at maximum growth rate (g) 26.8 (0.28) 31.5 (0.52) 
2 a2 x b2 Maximum growth rate (g/PND) 0.062 (0.01) 0.116 (0.01) 
2 d2 Age at maximum growth rate (PND) 164.3 (6.7) 154.2 (5.8) 
  Values are means (SE), with significance at p < 0.05 shown in bold. Parameters were 
estimated from a diphasic sigmoidal curve (Koops et al. 1987), where Growth phase = 1 
denotes prepubertal, and = 2 postpubertal, respectively. 
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Table 3-2. Effects of dietary fat on body growth characteristics in the PyMT model. 
Growth 
phase 
Parameter Interpretation LFD HFD 
1 a1 Weight at maximum growth rate (g) 11.5 (0.16) 12.0 (0.18) 
1 a1 x b1 Maximum growth rate (g/PND) 0.639 (0.02) 0.721 (0.02) 
1 d1 Age at maximum growth rate (PND) 18.9 (0.45) 17.6 (0.41) 
 Values are means (SE), with significance at p < 0.05 shown in bold. Parameters were 
estimated from a monophasic sigmoidal curve (Koops et al. 1987), growth phase = 1 
denotes prepubertal growth. 
. 
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Table 3-3. Comparison of body growth characteristics among breast cancer models 
maintained on HD.  
Growth 
phase 
Parameter Interpretation FVB PyMT HER2 DMBA 
1 a1 Weight at 
maximum growth 
rate (g) 
12.1 
(0.12) 
12.0 
(0.18) 
13.5 (1.6) 10.7 (0.45) 
1 a1 x b1 Maximum growth 
rate (g/PND) 
0.681 
(0.03) 
0.721 
(0.02) 
0.761 
(0.07) 
0.729 (0.02) 
1 d1 Age at maximum 
growth rate 
(PND) 
21.3 
(0.43) 
17.6 
(0.41) 
20.5 (1.3) 16.7 (0.29) 
2 2a1 + a2 Weight at 
maximum growth 
rate (g) 
  44.8 
(23.9) 
31.5 (0.5) 
2 a2 x b2 Maximum growth 
rate (g/PND) 
  0.0947 
(0.07) 
0.116 (0.01) 
2 d2 Age at maximum 
growth rate 
(PND) 
  332.7 
(233.7) 
154.2 (5.8) 
   Values are means (SE), with intermodel significant differences at p < 0.05 noted by lines. 
Parameters were estimated from monophasic and diphasic sigmoidal curves (Koops et al. 
1987), where growth phase = 1 denotes prepubertal, and = 2 postpubertal, respectively. 
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Table 3-4. Comparison of metabolic syndrome phenotypes among breast cancer models 
maintained on HD.  
Phenotype FVB DMBA PyMT HER2 
BW at PND 35 20.4 (0.57) 20.7 (0.21) 21.0 (0.40) 23.7 (0.31) 
Body fat at PND 35 21.0 (2.3) 22.0 (3.3) 20.8 (2.6) 26.2 (2.2) 
Glucose at PND 35 104.9 (27.0) 111.4 (29.1) 83.9 (23.5) 92.1 (15.8) 
BW at PND 90  25.2 (0.74) 25.1 (0.32) 20.1 (0.48) 29.4 (0.85) 
Body fat at PND 90 27.3 (4.2) 25.0 (3.5) 29.4 (4.0) 31.9 (4.5) 
BW at PND 120 27.8 (1.3) 28.1 (0.44)  29.5 (0.92) 
Glucose at PND 120  118.2 (26.9) 129.3 (24.6)  93.8 (21.7) 
TAG at sacrifice  128.6 (15.4) 193.5 (31.3)  172.6 (20.8) 179.8 (49.6) 
  Values are means (SE), with intermodel significant differences at p < 0.05 noted by lines. 
Means were estimated from monophasic and diphasic sigmoidal curves for BW (body 
weight, g) (Koops et al. 1987), from linear mixed models for fasting blood glucose 
(glucose, mg/dL) and body fat (%), and from ANOVA for serum triglycerides (TAG, 
mg/dL).  
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Table 3-5. Estrogenic activity of organic fraction of diets. 
Diet Extract 
Concentration 
(g/ml) 
EC50 Standards 
(pg E2) 
EC[x] for 
Sample (g Diet 
Equivalents) 
Induction 
Equivalent pg 
E2/ g Diet 
Equivalents 
LD 2.500  0.07352 0.00705 
[50.0%] 
10.43* 
HD 2.502  0.19172 0.05150 
[18.6%] 
3.72 
Values are means (SE), based on triplicates with inter-diet significant differences at 
ANOVA p < 0.05 noted by *.  
 
FIGURE LEGENDS 
 
Figure 3-1.  Schematic of DMBA, HER2, and PyMT breast cancer models and FVB 
controls. Numbers in 2 x 2 tables represent the number of litters per treatment group.   
Euth. represents euthansia of FVB. Cancer models are euthanized after palpation when 
lesion ≥ 1 cm or at PND 330. 
 
Figure 3-2. Metabolic syndrome in DMBA mice. HFD increases a) body weight, b) 
percent body fat, and c) blood glucose over LFD.  d) Triglycerides are not impacted by 
diet. 
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Figure 3-3. Metabolic syndrome in PyMT mice. HD increases a) body weight, b) percent 
body fat, but not c) blood glucose.  d) Triglycerides are altered by HD and TCDD. 
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Figure 3-2.
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  CHAPTER 4  
 
MATERNAL DIOXIN EXPOSURE COMBINE WITH A DIET 
HIGH IN FAT IN FAT INCREASES MAMMARY CANCER 
INCIDENCE THROUGH CYP1B1- AND COMT- MEDIATED 
ESTROGEN METABOLISM1 
 
ABSTRACT 
 
Epidemiological studies show that breast cancer risk correlates with total lifetime 
exposure to estrogens and that early life 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
exposure can also increase cancer risk. Because both TCDD and adipocytes impact the 
estrogen pathway, we examined how TCDD and an obesegenic diet interact to alter 
breast cancer susceptibility. At 12.5 days post coitus, we exposed pregnant FVB/NJ 
female mice to 1 µg/kg of TCDD or vehicle and at parturition randomly assigned the 
nursing dams to a low- or high-fat diet (HFD).  Female offspring were maintained on the 
same diets after weaning and exposed to 7,12-dimethyl-benz[a]anthracene (DMBA) at 
                                                
1 Rachel Harper preformed mammary tissue rtPCR, as well as mammary tissue and tumor 
real time PCR. 
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post-natal days (PND) 35, 49 and 63 to initiate mammary tumors.  A second cohort of 
females was treated identically until PND 35 or 49, when mammary gland morphology 
was examined, or at PND 50, when mammary gland mRNA and ERBB2 was analyzed. 
We found that a combination of maternal TCDD exposure and HFD increases mammary 
tumor incidence. Among mice fed HFD, maternal TCDD exposure caused rapid 
mammary development and increased Cyp1b1 expression and decreased Comt expression 
in mammary tissue. Mammary tumor Cyp1b1 expression was also increased by maternal 
TCDD exposure. Our data suggest that HFD increases sensitivity to maternal TCDD 
exposure, resulting in increased breast cancer incidence through changes in the timing of 
mammary differentiation and estrogen metabolism during puberty.  
 
Introduction 
 
Total lifetime exposure to estrogen (E2) is the single greatest environmental risk 
factor for breast cancer (Dunn et al. 2005). The classic pathway of E2-mediated 
carcinogenesis is through the estrogen receptor (ER), where E2 alters gene expression to 
increase cell proliferation (Currier et al. 2005). Consequently, it has been hypothesized 
that E2 metabolism acts to decrease breast cancer risk (Holcomb and Safe 1994). Yet, 
some estrogen metabolites may increase breast cancer risk through DNA damage 
(Cavalieri and Rogan 2004; Cavalieri et al. 1997). E2 is metabolized into reactive 
catechols primarily by CYP1B1 (Lee and Zhu 2006). The catechols undergo redox 
cycling resulting in oxidative stress, DNA adduct formation, and DNA mutations 
(Cavalieri and Rogan 2004; Chakravarti et al. 2001; Mitrunen and Hirvonen 2003). The 
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phase II enzyme catechol-o-methyltransferase (COMT) can mitigate this genotoxicity by 
inactivating the E2-catechol by O-methylation. 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
(TCDD) and other aryl hydrocarbon receptor (AhR) agonists can modulate estrogen 
activity through induction of estrogen-metabolizing CYP1 enzymes (Mitrunen and 
Hirvonen 2003; Tsuchiya et al. 2005). Thus TCDD and other AhR agonists have the 
potential to modify breast cancer risk through alteration of ER-mediated proliferation or 
CYP1-mediated DNA damage (Mitrunen and Hirvonen 2003; Ohtake et al. 2003; Safe et 
al. 2000). The influence of TCDD exposure may be more pronounced at younger ages 
since early life estrogenic exposures contribute to a greater risk of breast cancer than 
exposures later in life (Dolinoy et al. 2007b; Hilakivi-Clarke et al. 2000; Hilakivi-Clarke 
et al. 1999; Hilakivi-Clarke et al. 1997).  
An industrial accident in Seveso, Italy supports the link between early TCDD 
exposure and cancer risk. TCDD exposure was positively associated with breast cancer 
risk only in women who were infants to 40 years of age at the time of the industrial 
accident (Warner et al. 2002).  Early life TCDD exposure, particularly perinatally, has 
also been associated with increased mammary cancer in several rodent models (Brown et 
al. 1998; Desaulniers et al. 2001). Paradoxically, while greater estrogen exposure seen in 
adolescents with early menses contributes to increased breast cancer risk (Vihko and 
Apter 1984), delayed pubertal breast differentiation may also increase breast cancer risk. 
Rodent models have shown that perinatal TCDD exposure increases mammary cancer 
risk through altered mammary differentiation (Brown et al. 1998; Fenton et al. 2002), 
which extends the period in which the rapidly proliferating progenitor cells of the 
terminal end buds (TEB) are susceptible to carcinogenic insult (Birnbaum and Fenton 
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2003).  A similar delay is seen in humans. As premenarcheal serum TCDD 
concentrations increase, the timing of pubertal breast development is delayed (Den Hond 
et al. 2002).  
Obesity, like TCDD and E2 exposures, may have age- or developmental stage- 
specific effects on breast cancer risk (De Assis and Hilakivi-Clarke 2006). Childhood 
obesity appears to protect against breast cancer despite synthesis of E2 in adipose tissue 
(De Assis and Hilakivi-Clarke 2006). The adipose synthesis of E2 likely contributes to 
precocious pubertal mammary development, and if obesity and weight gain extend into 
adulthood, increased post-menopausal breast cancer risk (Britton et al. 2004; De Assis 
and Hilakivi-Clarke 2006; Hakkak et al. 2007; Stoll 1998). Obesity may also modify 
breast cancer risk through increased persistence of lipophilic TCDD in adipose tissue, 
including mammary stroma (Emond et al. 2006). Mammary glands of obese individuals 
are likely exposed to greater TCDD levels than lean counterparts because of increased 
dietary TCDD concentrations in animal products and increased TCDD persistence 
(Emond et al. 2006; Harrad et al. 2003; Hooper et al. 1998; Michalek and Tripathi 1999). 
Because obese individuals retain more TCDD, maternal TCDD exposure may result in 
altered susceptibility to breast cancer among their offspring. Here the 7,12-dimethyl-
benz[a]anthracene (DMBA) mouse model of breast cancer was used to examine the 
etiological basis of how maternal TCDD exposure and high-fat diet (HFD) increase 
cancer risk. We report that the combined effect of maternal TCDD exposure and HFD 
increases mammary cancer risk through alterations in E2 metabolism and mammary 
gland remodeling.  
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RESULTS 
 
Maternal TCDD exposure and HFD increase mammary tumor incidence. 
Palpable lesions of both dermal and mammary origin were found after DMBA exposure, 
with the majority of DMBA-treated mice developing dermal lesions. The palpable lesion 
latency was shorter for DMBA fed HFD than those fed LFD (HR = 0.0075, p < 0.01) and 
the lesions grew faster (HR = 0.24827, p < 0.05). Consistent with previous rat studies 
(Brown et al. 1998; Desaulniers et al. 2001), DMBA-treated mice fed LFD after maternal 
TCDD exposure had shortened lesion latency compared to those treated with vehicle (HR 
= 2.01081, p < 0.05), although the number of mammary tumors was not effected. 
Because of the increased mammary tumor incidence with either obesity or 
perinatal TCDD exposure seen in previous studies ((Brown et al. 1998; Desaulniers et al. 
2001; Hakkak et al. 2007), it was anticipated that DMBA fed HFD might have 
heightened susceptibility to maternal TCDD exposure. Consistent with this expectation, 
there was a significant increase in mammary lesions of mice fed HFD after maternal 
TCDD exposure (p < 0.0001, Fig. 4-1A). DMBA fed HFD had substantially more 
mammary tumors than DMBA fed LFD. Only two mammary lesions occurred in DMBA 
on LFD, and neither of these mice were treated with TCDD. While no mammary tumors 
arose in litters exposed to TCDD and LFD, and one third of unexposed litters fed HFD 
had mammary tumors, every litter exposed to both TCDD and HFD developed mammary 
tumors. Among DMBA treated mice fed HFD, TCDD exposure appeared to double 
mammary tumor incidence (Fig. 4-1A). Mammary lesions were primarily squamous cell 
carcinomas, typical of the DMBA model (Fig. 4-1B), and this was not altered by 
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treatment. However, several lesion types were clustered with respect to treatment. Three 
adenomyoepitheliomas, a rare lesion in the DMBA models, were found exclusively in 
DMBA treated mice fed HFD whose dams were treated with TCDD (Fig. 4-1C).  In 
DMBA fed HFD without TCDD exposure, two solid nodular ERBB2-positive tumors 
were found with zonation (Fig. 4-1D; (Rosner et al. 2002).  
  
Maternal TCDD exposure and HFD transiently alter pubertal mammary gland 
morphology. Previous reports demonstrated a correlation between perinatal TCDD 
exposure, altered pubertal mammary differentiation, and increased mammary tumors 
(Brown et al. 1998; Fenton et al. 2002). Maternal TCDD and HFD exposures had 
significantly non-additive effects on the number of TEB at PND 35 (p < 0.001, Fig 4-2). 
Among DMBA treated mice fed LFD, there were 22 TEB more with maternal TCDD 
exposure compared to vehicle, whereas among DMBA treated mice fed HFD, there were 
18 TEB less with maternal TCDD exposure (p < 0.01, Fig. 4-2). While mean fat pad 
length, TEB number, and branch elongation were greater among DMBA treated mice fed 
HFD relative to LFD, only branch elongation was significantly increased in the HFD 
group at PND 35 (p < 0.05, data not shown). Though perinatal TCDD exposure in rats 
prevented the full differentiation of pubertal mammary glands (Fenton et al. 2002), we 
found the effects to be transient.  By PND 49, neither HFD- nor maternal TCDD- 
exposure impacted the fat pad length, number of TEB, or ductal elongation (data not 
shown). Further, at PND 50, there were no treatment-associated changes in mammary 
morphology regulators Egf and Ereg mRNA (data not shown). 
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Maternal TCDD exposure alters E2 metabolism in mice fed HFD. At PND 50, we 
explored what transcriptional changes contributed to the progression of mammary 
carcinogenesis. Because mammary carcinogenesis involves either E2-ER mediated 
proliferation or E2-metabolite mediated genetic instability (Bolton and Thatcher 2008) 
(Fig. 1-1), we surveyed the genome for indications of these mechanisms. Cyp1a1, 
Cyp1b1, and Comt were examined as indicators of E2 metabolism. Exposure to HFD and 
maternal TCDD increased epithelial Cyp1b1- and decreased Comt- mRNA in mammary 
glands, though TCDD had no effect on expression in DMBA treated mice fed LFD (p < 
0.05, Fig. 4-3A-B). Cyp1b1 was also increased in mammary tumors compared to 
matched, normal mammary glands (p < 0.05, Fig. 4-3C). Among mammary tumors, 
Cyp1b1 was elevated by maternal TCDD exposure relative to vehicle (p < 0.05, Fig. 4-
3C). Our model suggested this was more than an additive interaction between TCDD and 
tumor tissue on Cyp1b1 expression (p = 0.08, Fig. 4-3C). There was no change in 
Cyp1a1, Ccdm1, Cmyc, Egfr, Esr1 or Esr2 mRNA in the mammary glands. Together this 
suggests that genomic instability caused by E2-metabolites, and not E2-ER mediated 
proliferation, could be the mechanism underlying cancer progression (Fig. 1-1). Global 
gene expression analysis demonstrated a subtle role for pubertal onset of obesity in 
modifying metabolism of carbohydrates, lipids and proteins (data not shown).  
Microarray analysis indicated significantly reduced Comt and Insig in the PND 50 
mammary glands of DMBA treated mice fed HFD (FDR δ < 0.05) and these trends were 
confirmed by real time PCR. TCDD exposure was not associated with any global changes 
in gene expression at the time-point examined. 
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DISCUSSION 
 
Human and rat studies suggest early life TCDD exposure increases mammary 
cancer incidence (Brown et al. 1998; Desaulniers et al. 2001; Warner et al. 2002), and 
this study extends these observations to mice fed HFD. Though the TCDD dose was 
higher than most acute human exposures, it is nonetheless considered very low for mice. 
There is substantial evidence that maternal estrogenic exposures increase E2-responsive 
cancer incidence in adult offspring (Brown et al. 1998; Ho et al. 2006; Li et al. 1997; 
Prins et al. 2008). Several studies implicate a role of maternal COMT and CYP1B1 in 
daughter’s breast cancer risk (Inoue et al. 1980; Sata et al. 2006) (Ahsan et al. 2004). 
Thus TCDD-induced Comt and Cyp1b1 changes in utero could be partially responsible 
for genetic instability leading to mammary tumors seen here.  
This study addressed whether HFD and maternal TCDD exposure increases breast 
cancer risk through the E2-ER proliferation pathway, the E2-metabolism pathway, or 
through mammary structural remodeling (Fig. 1-1). TCDD modestly upregulated 
epithelial Cyp1b1 and decreased Comt expression in mammary glands from DMBA fed 
HFD, supporting a role of the E2-metabolism pathway in cancer etiology. While modest 
changes are common in constitutive Cyp1b1, environmental exposures infrequently 
change Comt expression. In one rat model aryl hydrocarbon exposure decreased hepatic 
Comt expression (Desaulniers et al. 2005). Human studies have sometimes shown that 
high activity Cyp1b1 alleles and low activity Comt alleles are associated with increased 
risk of breast cancer (Wen et al. 2007), and of other E2- responsive cancers (Nock et al. 
2006; Sellers et al. 2005; Zimarina et al. 2004). Interactions between E2 exposures 
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during key life stages and E2-regulating genes, CYP1B1 and COMT, may modify breast 
cancer risk (Mitrunen et al. 2001).  
In this study, DMBA treated mice fed HFD had increased mammary lesion 
incidence and shortened latency relative to those fed LFD. We have shown previously 
that HFD increased adiposity and fasting blood glucose from puberty throughout life 
(Chapter 3). Consistent with their elevated glucose, we demonstrate that these mice had 
decreased Insig1 during carcinogenesis (Nakagawa et al. 2006). Thus the DMBA treated 
mice fed HFD had greater adiposity and type II diabetes risk than those fed LFD. Obesity 
increases post-menopausal breast cancer in women (Lorincz and Sukumar 2006), which 
may occur because of  heightened E2 production in mammary adipose tissue (Hakkak et 
al. 2007; Simpson 2003). Further, several studies have found that increased adiposity 
interacts with alleles of E2 metabolizing enzymes to increase breast cancer risk (Kocabas 
et al. 2005; Kocabas et al. 2002; Thompson et al. 1998). Thus the doubled mammary 
tumor incidence in HFD fed mice exposed to maternal TCDD here may reflect higher 
steady state levels of both E2 and its toxic metabolites (Fig. 1-1). 
Maternal TCDD substantially increased Cyp1b1 expression in mammary tumors, 
suggesting that changes in mammary progenitor cells resulted in increased Cyp1b1 that 
persisted through their expansion to tumors (Brown et al. 1998; Feinberg et al. 2006; 
Fenton et al. 2002). Unlike what was seen in mammary lesion incidence, DMBA treated 
mice fed HFD and exposed to TCDD had reduced TEB number during can initiation. 
Since TEB number correlates to carcinogenicity of DMBA, this TCDD effect was 
unexpected (Russo and Russo 1978). Mammary gland morphology was unchanged by 
diet and maternal TCDD at subsequent ages. The low Comt seen in these mice supports 
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this increase in the speed of their pubertal breast development (Eriksson et al. 2005), 
which could increase risk of DNA damage (Cavalieri and Rogan 2004; Chakravarti et al. 
2001; Russo and Russo 1978). Together our data suggests rapid compensatory growth in 
mammary glands exposed to HFD and maternal TCDD, and when Comt was decreased 
and epithelial Cyp1b1 was increased, increased susceptibility to mammary carcinogenesis 
resulted.   
In summary, maintenance of mice on HFD increased the effects of maternal 
TCDD on offspring breast cancer risk through alterations in mammary gland- 
morphology and gene expression. E2-like exposures, such as an obesegenic diet and a 
low dose of TCDD during gestation, may increase the risk of association between 
Cyp1b1, Comt, and adult breast cancer. The inconsistent relationships between CYP1B1, 
COMT, and breast cancer risk seen across epidemiology studies may reflect divergent 
risk between those who have had substantial environmental E2 exposure and those who 
have not (Justenhoven et al. 2007; Le Marchand et al. 2005; McGrath et al. 2004). This 
may understate the susceptibility to TCDD among obese, genetically- susceptible women. 
This highlights the importance of using experimental animal models to evaluate the 
unique susceptibilities of varying subpopulations to breast cancer risk, and to ensure risk 
assessments in humans do not fail to take susceptible subpopulations into account. 
 
MATERIALS AND METHODS 
 
Mice and experimental design. We studied the effects of HFD and maternal 
TCDD exposure in a randomized 2 x 2 factorial design using the TCDD-responsive 
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mouse strain, FVB/NJ (FVB, Jackson Laboratories, Bar Harbor, ME; (Jones et al. 1991). 
We have shown previously that FVB are responsive to HFD, gaining body weight and 
adiposity along with elevated fasting blood glucose levels. At 12.5 days post coitus 
(DPC), 1 µg/kg of TCDD (p. o., n = 13 dams, 1.8-1.9 µl TCDD solution/g mouse, 99.9% 
purity, Ultra Scientific, North Kingstown, RI), or equivalent volume of vehicle (p. o., 
95%/5% olive oil/toluene by volume, n = 15 dams, 99.9% purity, Sigma-Aldrich, St. 
Louis, MO) was administered to nulliparous FVB females. FVB litters were assigned to 
HFD or matched control low fat diet (LFD; D12451 n = 14 litters and D12450B n = 15 
respectively, Research Diets, New Brunswick, NJ) from post-natal day (PND) 0 
(parturition) until euthanasia. At PND 4, all litters were culled to 4 pups, maximizing the 
number of female pups per litter. At PND 21, all dams and any male offspring were 
removed from the cage. At PND 35, 49 and 63, 60 mg/kg of DMBA (p. o., 2.4 µl DMBA 
solution/g mouse, 95%/5% olive oil/toluene by volume, 98% purity, Sigma-Aldrich, St. 
Louis, MO) was administered. A second cohort of FVB were treated identically until 
euthanizing to examine mammary gland morphology (PND 35, 49), mRNA (PND 50), 
and protein (PND 50). DMBA mice were palpated for mammary lesions biweekly 
beginning at PND 83. All mice were given water ad libitum in sterile ventilated cages in 
an American Association for the Accreditation of Laboratory Animal Care-approved 
facility. Euthanasia was performed with CO2 asphyxiation on PND 35, 49 and 50, and 
when lesions were ≥ 1 cm, or at 11 months of age, whichever came first.  
 
Histological analyses. Mammary lesions were bisected at necropsy.  One lesion 
half was fixed overnight at 4C in 4% paraformaldehyde before dehydrating, embedding 
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in paraffin, and sectioning. Hematoxylin and eosin (H&E) staining was used to diagnose 
lesion pathology. Immunohistochemical analysis of ERBB expression was preformed 
according standard methods. Briefly, 4-µm paraffin sections were placed onto 
Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA), deparaffinized, and cleared. IHC 
was performed after inhibition of endogenous peroxidase activity in a solution of 3% 
hydrogen peroxide in methanol and hydration in graded alcohol to distilled water. 
Antigen retrieval was performed by high temperature and pressure incubation in 0.01 
mol/L of citric acid buffer (pH 6.0) for 3 x 4 minutes. Slides were allowed to cool for 30 
minutes in citric acid buffer then transferred to phosphate-buffered saline (pH 7.4) (2 x 5 
minutes each). Universal blocking reagent (BioGenex, San Ramon, CA) was applied to 
sections and incubated for 30 minutes in a humidified chamber at room temperature. 
ErbB2 and secondary antibodies (Neomarkers, Fremont, CA) diluted in PBS –Ova 
(albumin) were incubated for one hour each, and rinsed in PBS. Inguinal mammary 
glands from mice at PND 35 and 49 were weighed, fixed and Carmine Alum stained to 
evaluate fat pad length, number of TEB, and branch elongation according to published 
methods (Fenton et al. 2002). 
 
Gene expression. The other half of each mammary lesion and a grossly normal 
gland from the same mouse were flash frozen and pulverized for RNA extraction (TRIzol 
Reagent, Invitrogen, Carlsbad, CA). PND 50 mammary glands were flash frozen, 
pulverized, and pooled within litter for RNA extraction (TRIzol Reagent, Invitrogen).  
The High Capacity cDNA archive kit (ABI, Foster City, CA) was used to generate cDNA 
for PCR analysis.  Real time PCR was performed to assess relative transcript levels of 
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Cyp1a1, Cyp1b1, Insig, Ccdm1, Cmyc, Egf, Ereg, Esr1 and Esr2 using Assays-on-
Demand (ABI) with Gusb as the endogenous control and K18 as the epithelial marker in 
PND 50 mammary glands. Real time PCR was also preformed on Cyp1b1 and Comt to 
determine relative transcript levels using Tbp as the endogenous control in mammary 
tumors and matched controls (ABI). Global gene expression changes in PND 50 
mammary glands were assessed using a 4 x 44k chip (Agilent, Santa Clara, CA)(Syed 
and Threadgill 2006).  
 
Statistics. Lesion latency, defined as time (PND) to reach palpable lesion, and 
lesion aggression, defined as the time from first palpable mass to time of mass ≥ 1 cm 
(PND), were evaluated using a mixed survival model in SUDAAN 9.0 software, with 
litter as a random effect. Lesion incidence, defined as the proportion of mice with 
mammary lesions per litter, was analyzed with Fisher’s exact test (SAS 9.1.3, Cary, NC). 
ANOVA was used to evaluate the fixed effects of HFD and maternal TCDD and their 
interaction on branch elongation, fat pad length, number of TEB in PND 35 and 49 
mammary glands, and on Comt, Cyp1a1, Cyp1a2, Cyp1b1, Areg, Ereg, Ahr, Egfr, Esr1 
and Esr2 levels in PND 50 mammary glands (Proc GLM). The fixed effects of tissue 
status (tumored or normal) and maternal TCDD, their interaction, and litter as a random 
effect were model on Comt and Cyp1b1 levels in mammary tumors and matched tissue 
(Proc GLM). Microarrays were scanned on an Agilent scanner and analyzed using default 
settings of Feature Extraction version 9.1 (Agilent technologies, Santa Clara, CA). 
Microarray raw data were uploaded into the UNC Microarray Database and Log2 R/G 
Lowess normalization was performed on the Cy3 and Cy5 channels. The microarray data 
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are available at UNC Microarray Database (UNC 2008). The Lowess normalized data 
was quantile normalized (Barbacioru et al. 2006; Yang and Thorne 2003). Differentially 
expressed genes were identified using SAM software (Stanford, CA; (Tusher et al. 2001). 
Significance of IHC florescence was determined according to published methods (Rosner 
et al. 2002). 
 
FIGURE LEGENDS 
 
Fig. 4-1. HFD and maternal TCDD altered mammary tumor incidence and pathology. (A) 
HFD and maternal TCDD increase mammary tumor incidence (p < 0.0001, n = 28 
litters).  (B) Squamous cell adenocarcinoma typical of the DMBA model. (C) 
Adenomyoepithelioma in DMBA fed HFD and exposed to TCDD. (D) ErbB2-positive 
tumor in DMBA fed HFD.  
 
Fig. 4-2. Interaction of HFD and maternal TCDD on terminal end bud numbers at PND 
35. Means + SE are shown (p < 0.01, n = 20 litters). 
  
Fig. 4-3. HFD and maternal TCDD increase E2 metabolism. Fold change of real time 
PCR data determined by ∂∂CT method (Livak and Schmittgen 2001). (A) Comt mRNA is 
decreased in mammary glands exposed to HFD and maternal TCDD (p < 0.05, n  = 20 
mRNA pooled within litter). (B) Epithelial Cyp1b1 mRNA is increased in mammary 
glands exposed to HFD and maternal TCDD (p < 0.05, n  = 20 mRNA pooled within 
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litter).  (C) Cyp1b1 is elevated in mammary tumors by maternal TCDD exposure (p < 
0.05, n = 10 mammary tumors and 9 matched normal glands). 
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 CHAPTER 5 
CONCLUSION 
Total lifetime estrogen (E2) exposure increases mammary cancer risk. TCDD 
indirectly affects E2 signaling through many mechanisms, and early life TCDD 
exposures are also implicated in breast cancer. E2 produced by adipose tissue is the 
underlying mechanism by which obesity contributes to early puberty, and if obesity and 
weight gain extends into adulthood, increased post-menopausal breast cancer risk 
(Britton et al. 2004; De Assis and Hilakivi-Clarke 2006; Stoll 1998). Greater TCDD 
stores in the adipose of obese women have the potential to further increase cancer risk. 
I examined how environmental exposures can modify the molecular and physical 
structure of the mammary gland. The treatments examined were maternal exposure to 
TCDD, lifelong exposure to high fat diet (HFD) and pubertal exposure to DMBA. The 
prediction was that high fat diet and gestational exposure to TCDD would interact to 
increase mammary cancer risk, through both structural remodeling of the pubertal gland 
and through direct molecular actions (Fig. 1-1). Molecular changes potentially underlying 
these phenotypes were evaluated with particular emphasis on E2 (Fig. 1-1).  The 
physiological effects, e.g. growth trajectories, adiposity, blood glucose levels, and 
mammary gland development, of HFD and maternal TCDD were examined as potential 
causal intermediates leading to altered mammary gland phenotypes. Interactions of these 
exposures and physiological effects were explored in several mouse strains and mouse 
models of breast cancer. However, these objectives were primarily pursued using the 
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DMBA model of mouse mammary carcinogenesis. Here links between puberty, 
metabolic syndrome, environmental chemicals, and breast cancer etiology are examined. 
 
FINDINGS 
 
 The expression of an oncogene or exposure to a carcinogen increased the 
adiposity and speed of the pubertal growth spurt relative to controls. Consistent with this 
observation, the speed of the pubertal growth spurt is a risk factor for breast cancer 
(Forman et al. 2005). In the strains and breast cancer models we examined, HFD 
increased adiposity and body weight gain. In breast cancer models, HFD-induced 
increased body weights were seen from pre-weaning throughout life. Moreover, there 
were breast cancer model-specific physiological responses to HFD. The DMBA breast 
cancer model had more highly impaired glucose tolerance as compared to the other breast 
cancer models maintained on HFD. The quantity of blood sugar in fasting DMBA were 
above the threshold for increased risk of metabolic syndrome, making them at risk for 
HFD-induced type II diabetes (2001).  
Compared to other breast cancer models, the DMBA model had a relatively slow 
gain in HFD-induced adiposity. However, the DMBA model had greater adiposity and 
body weight gain through adulthood. This is consistent with human data, where obesity 
increases postmenopausal breast cancer risk. In the DMBA model mice fed HFD, 
mammary lesion incidence was doubled and latency was shortened relative to DMBA 
mice on LFD.  Very few DMBA mice maintained on LFD had mammary lesions, 
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regardless of TCDD exposure. However, maternal TCDD exposure doubled mammary 
lesion incidence among DMBA fed HFD.  
Analysis of pubertal mammary gland morphological changes provided insight 
into the mechanisms of DMBA carcinogenesis. Similar to the diet effect on mammary 
lesion incidence, DMBA fed HFD had more TEB than DMBA fed HFD at the time of 
initiation. However HFD and maternal TCDD exposure caused significantly non-additive 
changes in TEB number. In DMBA fed LFD, maternal TCDD exposure tripled the 
number of TEB. In contrast, in DMBA mice of the same age and fed HFD, TCDD cuts 
the number of TEB in half. Since TEB number correlates with the carcinogenicity of 
mutagens, such as DMBA, this TCDD effect was an unexpected result (Russo and Russo 
1978). To test the hypothesis that by reducing TEB number, TCDD delays the window of 
susceptibility to carcinogenic insult, we looked at gland morphology at the time of the 
second DMBA dose (Birnbaum and Fenton 2003). Mammary gland morphology was 
unchanged by HFD and maternal TCDD at post-natal day (PND) 49. This rapid 
mammary gland compensatory growth in DMBA fed HFD with maternal TCDD 
exposure may have increased their mammary lesion incidence. 
Molecular changes in the progressing mammary gland were also examined. Diet 
only had a modest effect on gene expression, though Insig and Comt were altered 
moderately. Further, maternal TCDD exposure caused no obvious global gene expression 
changes during progression. This small change in mRNA suggests that the proportion of 
epithelium to adipose in the progressing pubertal mammary gland did not shift due to 
these treatments, and that maternal TCDD did not alter epithelial morphology after an 
acute DMBA dose. More sensitive analyses demonstrated that among DMBA mice fed 
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HFD, maternal TCDD increased epithelial Cyp1b1 and decreased Comt expression in 
progressing mammary glands.  The effect of maternal TCDD on Cyp1b1 expression 
persisted in the mammary tumors.  
In summary, work described in this dissertation shows that maternal TCDD 
increases mammary lesions in mice fed HFD with high obesity and type II diabetes risk. 
This is consistent with the central hypothesis of this work, that high fat diet and 
gestational exposure to TCDD would interact to increase mammary cancer risk. Maternal 
TCDD exposure also caused diet-dependent effects in mammary gland pubertal 
development, blood glucose and percent body fat across models. In the DMBA model, 
these effects were transient and did not have the same HFD by TCDD interaction seen in 
mammary lesion incidence. Instead we found that maternal TCDD caused decreased 
Comt and increased epithelial and tumor Cyp1b1 in mammary glands of DMBA fed 
HFD. 
 
WHAT IS THE SIGNIFICANCE? 
 
 
It may be that susceptibility to obesity and breast cancer is determined by genetic 
responses to environmental risk factors for obesity and breast cancer (Han et al. 2004b; 
Hewitt 1997).  Several studies have shown that AhR ligands such as polycyclic aromatic 
hydrocarbons (PAHs) and polycyclic halogenated aromatic hydrocarbons (PHAHs) 
interact with the genotype of downstream transcription products to increase breast cancer 
risk (Ambrosone et al. 1995; Li et al. 2005b; Li et al. 2004).  TCDD can induce or inhibit 
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estrogenic effects because of AhR-estrogen receptor alpha (Erα) crosstalk or E2 
metabolism (Cavalieri and Rogan 2004; Ohtake et al. 2003; Safe et al. 2000)Fig. 1-1). If 
the E2-catechols formed by CYP1B1 during E2 metabolism are not conjugated by 
COMT, oxidative stress, DNA adducts and mutations may increase cancer risk (Cavalieri 
and Rogan 2004; DiGiovanni et al. 1986) Fig. 1-1). In this study genotoxic E2 
metabolites may have increased mammary cancer incidence. 
Timing is important for endocrine signals. E2 has both pro- and anti-estrogenic 
consequences depending on the age of the E2 exposure. Both in utero and preweaning E2 
exposures accelerates puberty onset, but whereas in utero E2 exposure increases 
carcinogen-induced mammary tumorigenesis, preweaning E2 exposures protect against 
carcinogen-induced mammary tumorigenesis (Cabanes et al. 2004; De Assis and 
Hilakivi-Clarke 2006; Hilakivi-Clarke et al. 1997).  
TCDD exposure can also negatively and positively correlate with breast cancer 
incidence (Brown et al. 1998; Holcomb and Safe 1994). While TCDD reduces mammary 
tumor incidence and even size when given to adult female rodents (Holcomb and Safe 
1994), similar to E2, in utero TCDD exposure increases carcinogen-induced mammary 
tumorigenesis (Brown et al. 1998). Increased terminal end buds and decreased lobules 
suggest delayed mammary maturation in these same rats exposed to TCDD at mid-
gestation (Brown et al. 1998), however in this study accelerated puberty mammary 
growth appeared linked to cancer incidence. This heightened mammary tumor 
susceptibility may result from more rapidly developing pubertal mammary glands or 
from mammary developmental reprogramming (Fenton et al. 2002; Russo and Russo 
1978).  As early as PND 4, mammary glands from mice gestationally exposed to TCDD 
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had reduced mammary gland development, and delayed mammary puberty and 
permanently altered gland morphology (Fenton et al. 2002).  
Obesity may also extend the period of pubertal mammary development(Simpson 
2003), although prepuberty adiposity makes inconsistent predictions of early onset breast 
development (Britton et al. 2004; Forman et al. 2005). These inconsistencies may be due 
to subpopulations of obese girls whose genetic susceptibility shifts the timing of pubertal 
breast development. For instance, the lower COMT activity allele likely causes 
inefficient metabolism of E2, which results in greater levels of active E2 systemically and 
an increase in the speed of puberty breast development in girls (Eriksson et al. 2005) Fig. 
1-1). Because of auto-amplification of E2 levels, this systemic E2 elevation could occur 
throughout early pubertal mammary development (Eriksson et al. 2005). Here we saw 
TCDD reduce TEB and ductal growth in high fat fed DMBA mice during cancer 
initiation, but no TEB changes were seen during cancer promotion/progression. This 
suggests that maternal TCDD exposure depressed carcinogen initiation, but did not cause 
an increase of DMBA susceptibility due to delayed mammary development later. The 
increase in E2 would result in increased E2-derived mutagenic metabolites in mammary 
epithelium with elevated CYP1B1 (Fig. 1-1). 
Altered E2 homeostasis is a potential mechanistic link between menarche and 
breast cancer (Fig. 1-1). However, caution is needed in linking pubertal mammary 
development to the risk of development of mammary cancer later in life. Accelerated, 
delayed or persistently altered mammary gland development may alter susceptibility to 
carcinogenic insult, and perinatal reprogramming of the gland may be the mechanism 
through which maternal TCDD exposure influences carcinogenesis in progeny. Such 
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reprogramming must involve more than altered gland morphology in obese DMBA mice 
(Brown et al. 1998; Fenton et al. 2002; Russo and Russo 1978). Results in this 
dissertation are nevertheless consistent with an increased susceptibility to later 
carcinogenic insult by in utero estrogenic exposures (Brown et al. 1998; Cabanes et al. 
2004; De Assis and Hilakivi-Clarke 2006; Hilakivi-Clarke et al. 1997). 
Multiple lines of evidence suggest that perinatal reprogramming of the mammary 
gland can increase susceptibility to mammary cancer, and this may be the mechanism of 
increased mammary tumor incidence in offspring fed HFD and maternally exposed to 
TCDD observed in present studies. First, the WNT pathway is involved in fetal 
mammary programming, puberty and in the DMBA model. WNT-dependent signals are 
involved in mammary bud formation at gestational day (GD)12.5, when dams were 
exposed to TCDD or vehicle (Robinson 2007). Bud formation is a critical imprinting 
period, therefore it is possible that on GD12.5, TCDD imprinted WNT. The mammary 
gland continues to develop postnatally, and at the next stage of mammary gland 
development, puberty, is again dependent on the canonical WNT/β-catenin pathway, 
including orchestration with ERα transcriptional regulation. The DMBA mouse model of 
breast cancer activates the canonical WNT/β-catenin pathway during carcinogenesis 
(Currier et al. 2005).  
Epigenetic changes in Cyp1b1 and Comt due to maternal TCDD exposure are 
possible additional mechanisms of fetal mammary programming could be (Fig. 1-1). 
There is substantial evidence to suggest that adult endocrine disease risk can be modified 
by environmental factors early in development, particularly through fetal epigenomic 
changes (Anderson et al. 2000; Dolinoy et al. 2007a; Junien and Nathanielsz 2007). 
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Maternal exposure can shift methylation patterns causing decreased reproductive health 
across generations and increased incidence of endocrine diseases such as obesity and 
cancer (Anway et al. 2005; Brown et al. 1998; Cropley et al. 2006; Dolinoy et al. 2007b; 
Ho et al. 2006; Li et al. 2003; Li et al. 1997; Prins et al. 2008). Further, CYP1B1 and 
COMT are implicated in mammary lesion incidence here, and their promoter methylation 
impacts endocrine cancers. CYP1B1 promoter methylation is associated with decreased 
survival of breast cancer patients, and its effect on E2 steady states profoundly impacts 
E2-targeted chemotherapy (Widschwendter et al. 2004). COMT methylation inactivates 
COMT in endometrial tumors, but not in control endometrium (Sasaki et al. 2003). 
Presently there was suggestive interaction (p < 0.2) between maternal TCDD and tissue 
status (normal vs. tumor) on Comt induction. Thus, it is possible that TCDD increases 
mammary cancer in DMBA mice because of interactions between TCDD-induced fetal 
programming and DMBA-induced WNT receptor signaling at puberty.  
The rapid compensatory growth during pubertal mammary development and the 
Comt and Cyp1b1 expression changes occurred only when DMBA offspring were 
exposed to maternal TCDD and fed HFD. However, the above hypotheses regarding 
maternal TCDD exposure do not fully explain the TCDD- increased incidence of 
mammary cancer in obese DMBA mice. To grasp this relationship between maternal 
TCDD and obesity, we must also consider the unique susceptibilities to maternal TCDD 
among the obese, possibly via differences in pharmacokinetic behaviors and estrogenic 
activities. 
Obese mice have less TCDD-binding protein in the liver, thus relatively more 
TCDD in fat compared to liver (Emond et al. 2006).  Because the larger size of the fat 
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compartment in DMBA fed HFD and maternally exposed to TCDD, the concentration of 
TCDD in the mammary fat pad may be lower. Offspring with increased body fat also 
eliminate TCDD at slower rates, making this acute dose more persistent in the mammary 
fat pads (DeVito et al. 2003; Michalek and Tripathi 1999). Since TCDD is in the 
mammary glands of DMBA fed HFD for longer times, this may result in greater TCDD 
effects in the mammary glands despite its lower concentration. These TCDD 
pharmacokinetic behaviors provide more opportunity for maternal TCDD to modify 
development and to postnatally imprint permanent changes on the mammary gland. 
Further, infants receive much of their mothers’ TCDD body burden through maternofetal 
transfer and breastfeeding. This exacerbates the potential risk of TCDD exposure because 
of the increased sensitivity at these developmental stages. 
 These obese by TCDD interactions on mammary cancer places focus on E2 and 
its receptor, ERα. TCDD, a potent AhR activator, could indirectly interact with ER in 
mammary fat pads and thereby increase mammary tumor risk. The activated AhR 
complex directly associates with ER, recruiting ER to estrogen response elements (ERE) 
on E2 promoters (Ohtake et al. 2003). This results in transcriptional- dependent 
downstream estrogenic-like activity in ovariectomized mice, but not in ovarierectomized 
mice with deficiency in either AhR or ER (Ohtake et al. 2003).  
It is commonly thought that extragonadal production of E2 poses an insignificant 
risk on breast cancer until menopause, but new lines of evidence are beginning to suggest 
otherwise. Adipose tissue produces E2, and excess adipose increases peripheral E2 levels 
(Simpson 2003). The decrease in Comt seen in DMBA fed HFD suggests that systemic 
E2 levels can increase also, at least during puberty (Eriksson et al. 2005; Fig.1-1). This 
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could cause greater proliferation through increased binding to ER, or if that saturates, 
increased genotoxicity through E2 metabolites (Fig 1-1). Obese mice and women have 
greater adiposity of their breasts and thus greater concentrations of E2 within their 
breasts. The role of adipocyte-produced E2 in mammary carcinogenesis has been recently 
demonstrated in several breast cancer models. HER2 breast cancer models are ER 
negative, and neither maternal TCDD nor obesity modifies their breast cancer risk 
(Cleary et al. 2004). However ER positive tumor incidence is increased in response to 
obesity (Cleary et al. 2004). Further, obese ovariectomized rats have increased mammary 
tumors compared to lean ovariectomized rats (Hakkak et al. 2007). Since obesity can 
increase cancer risk without central E2 production, it is feasible that the interaction 
between obesity and TCDD may increase steady state E2 levels in mammary tissue and 
tumors. This is noteworthy in part because obese women with ER positive breast cancers 
may be at a disproportional risk of breast cancer mortality because of the interaction of 
increased ERα and its ligand, E2 (Lorincz and Sukumar 2006).  
 
REMAINING QUESTIONS AND FUTURE DIRECTIONS 
 
 TCDD and HFD might interact to increase mammary lesion incidence through a 
number of plausible explanations involving pharmacokinetics and endocrine disruption. 
To expand this finding to account for TCDD exposure variation among natural 
populations would first require a dose response analysis. It may be that individual genetic 
susceptibilities to obesity is influenced by the genetic response to such environmental 
factors (Hewitt 1997), and this should be further explored in the adipose of both pubertal 
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and tumor-bearing mice. Investigating other endocrine disrupting lipophilic toxicants 
would shed further light on the existence of an ‘obese by endocrine disruptor in utero 
causes mammary cancer’ paradigm (Birnbaum and Fenton 2003; De Assis and Hilakivi-
Clarke 2006). The diet by TCDD relationships in fasting blood glucose and in mammary 
gland structure also needs further probing. Did the DMBA model develop type II diabetes 
and could this have influenced the mammary tumor etiology? Did the pubertal 
morphology of the gland influence its later mammary lesions and if so, how?  
TCDD exposure affected with pubertal blood glucose, pubertal mammary 
development and mammary lesion incidence by differing mechanisms; in each of these 
three phenotypes, the effect of maternal TCDD uniquely interacted with diet. Will we 
consistently find endocrine disruptors uniquely interact with obesity on endocrine 
systems that control type II diabetes risk, mammary puberty and mammary lesions? More 
mechanistic data would help to estimate the justification of any interspecies comparisons.  
How and when is TCDD altering Cyp1b1 and Comt expression? What physiological 
consequences ensue from this change? Additional studies are needed to examine the role 
of fetal TCDD exposure on epigenetic changes, particularly in the promoters of Cyp1b1 
and Comt. 
 We find that HFD contributes to an increase in adiposity, blood sugar, speed of 
pubertal mammary gland development and mammary lesion incidence. Here we show 
that TCDD doubles mammary lesion incidence among the obese. The interaction of HFD 
and TCDD on mammary tumor incidence is driven by alterations in the homeostasis of 
the one molecule consistently implicated in breast cancer risk: E2 (Fig. 1-1). This is 
likely due to increased mammary E2 production and increased E2-genoxicity in DMBA 
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mice that are maternally exposed to TCDD and fed HFD. TCDD-induced Cyp1b1 
expression in both mammary epithelia during carcinogenesis and in mammary tumors. 
These effects may further result from AhR-ERα receptor crosstalk (Ohtake et al. 2003), 
in utero gland programming (Fenton et al. 2002), and prolonged half-life of low dose 
TCDD in obese mice (Emond et al. 2006). These possibilities should be carefully 
examined in the future. 
This study examined how environmental estrogen exposures, such as obesegenic 
diet- and maternal TCDD exposure, impact breast cancer.  A better understanding of the 
biological and molecular history of breast cancer among the obese will support more 
informed choices for risk assessment and therapy.  Obesity is on the rise in children and 
adults, therefore we can expect health care expenditures relating to obesity to rise 
dramatically if intervention aimed at curtailing obesity fails (Popkin and Doak 1998; 
Popkin and Udry 1998).  Because of the ubiquity of TCDD exposure in humans, it is 
likely that everyone carries some TCDD burden, with those exposed to higher levels of 
TCDD during the 1960s and 1970s currently at the age where latent breast cancers will 
begin to develop. Although TCDD levels are likely low in most people, among obese 
women there is greater TCDD persistency (Emond et al. 2006). Obesity and maternal 
TCDD appear to be playing an etiological role in mammary cancer susceptibility through 
endocrine disruption. This may influence estrogen-targeted therapies. DMBA and TCDD 
represent PAHs and PHAHs, respectively, and are ubiquitous chemicals in the 
environment that occur as complex mixtures in human and environmental samples. These 
mixtures are overlapped by the increasing prevalence of obesity. Given the potential 
interactions of the obese phenotype with PAHs and PHAHs in altering breast cancer risk, 
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this study is highly relevant, as it has begun the evaluation of the patterns of 
carcinogenesis ensuing from exposures among the obese.  
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